[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 342
1. Gogo-Abite M, Seleye-Fubara D, Jamabo RS: Fibroadenoma coexisting with infiltrating ductal carcinoma--a case report. Niger J Med; 2005 Apr-Jun;14(2):221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fibroadenomas are benign breast tumours that are commonly diagnosed in young women in their 20's and early 30's.
  • Occurrence of malignancy in the breasts of these women is very rare.
  • METHOD AND RESULT: We report a case of an infiltrating ductal carcinoma within an otherwise benign fibroadenoma in a 23-year-old woman.
  • She presented with a lump, approximately 7cm in diameter, in her right breast.
  • CONCLUSION: Fibroadenomas are commonly diagnosed in patients in their 20's when the risk of developing breast cancer is extremely rare.
  • Despite this rarity all excised breast lumps should be subjected to histopathological evaluation in order to avoid a diagnostic pitfall.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083250.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


2. Shen C, Hu L, Xia L, Li Y: The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem; 2009 Feb;42(3):194-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR.
  • OBJECTIVES: To develop a specific, reliable assay for detecting circulating tumor cells (CTC) in peripheral blood of breast cancer patients.
  • DESIGN AND METHODS: 94 breast cancer patients, 35 patients with benign breast tumor, 40 healthy individuals, and 25 patients with other solid tumors were evaluated by quantitative real-time reverse transcription-PCR (qRT-PCR) for detecting Survivin, hTERT, and hMAM mRNA in peripheral blood (PB) of breast cancer patients.
  • RESULTS: The sensitivity of Survivin, hTERT, and hMAM mRNA in the PB of breast cancer patients was 36.2%, 59.6% and 33.0%, respectively.
  • Survivin and hTERT were detected in the PB patients with solid tumors other than breast cancer, but hMAM mRNA was only detected in breast cancer patients.
  • CONCLUSIONS: Survivin, hTERT and hMAM mRNA assays are powerful methods for detection of CTC of breast cancer patients.
  • With combination of the three markers for detection of CTC of breast cancer, the parallel test increases the sensitivity.
  • This analysis can offer a simple, noninvasive, and promising adjuvant tool for the early detection of micrometastatic tumor cells in breast cancer patients.
  • [MeSH-major] Breast Neoplasms / diagnosis. Neoplasm Metastasis / diagnosis. Neoplastic Cells, Circulating. RNA, Neoplasm / blood. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022237.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / DNA-Binding Proteins; 0 / Inhibitor of Apoptosis Proteins; 0 / MAML1 protein, human; 0 / Microtubule-Associated Proteins; 0 / RNA, Neoplasm; 0 / Trans-Activators; 0 / Transcription Factors; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


3. Yegingil H, Shih WY, Shih WH: Probing model tumor interfacial properties using piezoelectric cantilevers. Rev Sci Instrum; 2010 Sep;81(9):095104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probing model tumor interfacial properties using piezoelectric cantilevers.
  • Invasive malignant breast cancers are typically branchy and benign breast tumors are typically smooth.
  • It is of interest to characterize tumor branchiness (roughness) to differentiate invasive malignant breast cancer from noninvasive ones.
  • In this study, we examined the shear modulus (G) to elastic modulus (E) ratio, G/E, as a quantity to describe model tumor interfacial roughness using a piezoelectric cantilever capable of measuring both tissue elastic modulus and tissue shear modulus.
  • We constructed model tissues with tumors by embedding one-dimensional (1D) corrugated inclusions and three-dimensional (3D) spiky-ball inclusions made of modeling clay in gelatin.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Lead, elemental .
  • Hazardous Substances Data Bank. TITANIUM .
  • Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrasonics. 2000 Mar;38(1-8):400-4 [10829696.001]
  • [Cites] Arch Surg. 2001 Feb;136(2):204-8 [11177142.001]
  • [Cites] J Digit Imaging. 2002;15 Suppl 1:224-7 [12105735.001]
  • [Cites] Ultrasound Med Biol. 2003 Jun;29(6):813-23 [12837497.001]
  • [Cites] Annu Rev Biomed Eng. 2003;5:57-78 [12704084.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Jan;23(1):111-21 [14719692.001]
  • [Cites] Radiology. 1999 Jun;211(3):845-50 [10352614.001]
  • [Cites] Phys Med Biol. 2006 Jan 21;51(2):425-41 [16394348.001]
  • [Cites] Physiol Meas. 2005 Jun;26(3):215-28 [15798297.001]
  • [Cites] Phys Med Biol. 2007 Mar 21;52(6):1565-76 [17327649.001]
  • [Cites] Med Eng Phys. 2008 Oct;30(8):1013-9 [18495518.001]
  • [Cites] Rev Sci Instrum. 2007 Nov;78(11):115101 [18052498.001]
  • [Cites] Med Image Anal. 2007 Aug;11(4):361-73 [17509927.001]
  • (PMID = 20887005.001).
  • [ISSN] 1089-7623
  • [Journal-full-title] The Review of scientific instruments
  • [ISO-abbreviation] Rev Sci Instrum
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB000720; United States / NIBIB NIH HHS / EB / 1 R01 EB000720
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 12626-81-2 / lead titanate zirconate; 1302-87-0 / clay; 2P299V784P / Lead; C6V6S92N3C / Zirconium; D1JT611TNE / Titanium
  • [Other-IDs] NLM/ PMC2955722
  •  go-up   go-down


Advertisement
4. Duncan SF, Athanasian EA, Antonescu CR, Roberts CC: Resolution of Nodular Fasciitis in the Upper Arm. Radiol Case Rep; 2006;1(1):17-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nodular fasciitis is a benign fibroblastic lesion that was historically misdiagnosed as a malignant neoplasm.
  • After the diagnosis is established histologically, observation is the suggested treatment.
  • We present the case of a patient who had a large soft-tissue tumor in the upper arm with a clinical picture indicative of sarcoma, which ultimately was diagnosed as nodular fasciitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27298674.001).
  • [ISSN] 1930-0433
  • [Journal-full-title] Radiology case reports
  • [ISO-abbreviation] Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC4891406
  • [Keywords] NOTNLM ; MRI, magnetic resonance imaging
  •  go-up   go-down


5. Jukic DM, Drogowski LM, Davie JR: Carcinoma ex spiradenoma/cylindroma confirmed by immunohistochemical and molecular loss-of-heterozygosity profiling. Am J Dermatopathol; 2009 Oct;31(7):702-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient, a woman in her mid-70s, initially presented with separate mammary (ductal) carcinomas of the right and left breasts that were treated with radical mastectomies.
  • Histopathological exam revealed a benign eccrine spiradenoma/cylindroma and an intermixed carcinoma, with a differential diagnosis of either primary eccrine carcinoma or mammary carcinoma metastatic to the spiradenoma/cylindroma.
  • The mammary carcinomas showed disparate LOH at 5 of 7 (right breast) and 4 of 7 (left breast) informative genetic loci, establishing these carcinomas as separate primary neoplasms.
  • This neoplasm is referred to in the literature as carcinoma ex spiradenoma/cylindroma and spiradenocylindrocarcinoma.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Loss of Heterozygosity. Neoplasms, Second Primary / pathology. Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19684510.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Xing Y, Zhao JH, Wang TS, Qiao WL, Che WJ: [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
  • OBJECTIVE: To compare retrospectively the role of (18)F-FDG SPECT-CT and conventional imaging in the detection of recurrence and metastases in postoperative breast cancer patients with elevated level of tumor markers, and to evaluate the impact of (18)F-FDG SPECT-CT on the management of breast cancer patients.
  • METHODS: (18)F-FDG SPECT-CT was performed in 35 breast cancer patients with suspected recurrence based on elevated level of serum tumor markers.
  • The final diagnosis of recurrent breast cancer was confirmed by either pathology or observation by imaging during the follow-up for more than 1 year.
  • RESULTS: Among the 35 patients, the final diagnosis of recurrence or metastasis was established in 19 patients.
  • Of the 114 sites of increased FDG uptake, 93 were interpreted as malignant and 21 as benign.
  • CONCLUSION: In postoperative breast cancer patients with elevated level of tumor markers during the follow-up, (18)F-FDG SPECT-CT is more sensitive for detecting recurrence and metastases than conventional imaging.
  • [MeSH-major] Breast Neoplasms / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Breast Neoplasms, Male / blood. Breast Neoplasms, Male / pathology. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Whole Body Imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538891.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


7. Klifa CS, Shimakawa A, Siraj Z, Gibbs JE, Wilmes LJ, Partridge SC, Proctor E, Hylton NM: Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging; 2007 Jan;25(1):82-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of breast lesions using the 3D FIESTA sequence and contrast-enhanced magnetic resonance imaging.
  • PURPOSE: To determine whether combining 3D fast imaging employing steady-state acquisition (FIESTA) and T1-weighted contrast-enhanced (CE) sequences could help characterize lesions in 32 women with benign, in situ, or invasive breast lesions.
  • Since FIESTA provides both T1 and T2 information on the same three-dimensional (3D) matrix as high-resolution T1-weighted dynamic data, we aimed to verify whether invasive lesions could be separated from in situ and/or benign lesions using quantitative FIESTA measures of tissue intensity and homogeneity.
  • RESULTS: On FIESTA most invasive cancer lesions were hypointense compared to surrounding normal tissue (mean lesion intensity was 89% of normal tissue intensity), whereas most ductal and benign lesions appeared hyperintense compared to surrounding normal tissue (lesions at 100.9% and 121.9% of normal tissue intensity, respectively).
  • Measures obtained from resampled T2-weighted data showed no significant differences between the invasive and benign lesion groups.
  • [MeSH-major] Breast Neoplasms / diagnosis. Imaging, Three-Dimensional. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173311.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069587; United States / NCI NIH HHS / CA / R01 CA116182
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


8. Fulciniti F, Mansueto G, Vetrani A, Accurso A, Fortunato A, Palombini L: Metaplastic breast carcinoma on fine-needle cytology samples: a report of three cases. Diagn Cytopathol; 2005 Sep;33(3):205-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic breast carcinoma on fine-needle cytology samples: a report of three cases.
  • Metaplastic breast carcinoma (MBC) may have a varied presentation on fine-needle cytology samples.
  • Because of the various presentation of MBC on fine-needle cytology samples and the possible influence of needle "sampling" on the cytological specimen, the spectrum of differential diagnoses to be considered may encompass a number of benign and malignant entities, like keratinous subareolar cysts, malignant fibroepithelial lesions with myxo-chondroid stroma, and true sarcomas of the breast, with cartilaginous metaplasia.
  • It is the Authors' feeling that, with optimal samples, the cytomorphological findings of this rare variant of breast carcinoma permit its accurate pre-operative diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Carcinoma, Ductal / metabolism. Carcinoma, Ductal / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Sarcoma / metabolism. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16078244.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Dhillon R, Depree P, Metcalf C, Wylie E: Screen-detected mucinous breast carcinoma: potential for delayed diagnosis. Clin Radiol; 2006 May;61(5):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screen-detected mucinous breast carcinoma: potential for delayed diagnosis.
  • RESULTS: Of the pure mucinous carcinomas, the average age at diagnosis was 65 years (range 48-82 years), which was higher than that of other women with breast cancer (average age 60 years) screened at BreastScreen WA.
  • Only 39% (11/28) of tumours were detected at ultrasound, as the smaller lesions less than 15mm in diameter were often isoechoic with normal fat.
  • Where histological grade was reported at excision, most (25/26) were low to medium-grade tumours (Bloom, Richardson and Elston grade I and II).
  • A significant number of lesions (13/34) were evident on the previous screening examination where they were misinterpreted as benign lesions.
  • However, none of these cases had positive axillary lymph nodes at final diagnosis.
  • CONCLUSION: Although mammographically benign appearances of mucinous carcinoma caused a delay in diagnosis in 38% of the present cases, mucinous breast carcinomas have a favourable prognosis, as they are often low-grade tumours and rarely metastasize.
  • Delay in diagnosis for these tumours in a screening programme may not lead to a significant adverse outcome for most women.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Breast Neoplasms / radiography
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Ductal, Breast / ultrasonography. Databases, Factual. Female. Humans. Mammography / methods. Middle Aged. Neoplasm Invasiveness. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679116.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Giorgi Rossi P, Federici A, Farchi S, Chini F, Barca A, Guasticchi G, Borgia P: The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy. J Med Screen; 2006;13(3):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy.
  • In this study, we compare the incidences of treatments for benign and malignant neoplasms in the two groups.
  • We linked all incident cases of surgery for benign and malignant breast neoplasms, from the Hospital Information System (1999-2003) to the Mammographic Screening Information System (1999-2001).
  • We calculated incidence, adjusted for age and standardized breast cancer mortality ratio in each area of residence, for benign and malignant neoplasms surgery in non-yet-contacted and contacted woman.
  • RESULTS: The target population in Lazio is 681,000; 116,000 women were contacted during the study period and 3252 malignant and 1566 benign neoplasms were surgically treated.
  • Annual incidence was, respectively, 2.0/1000 and 1.1/1000 for malignant and benign neoplasms in women not contacted, and, respectively, 2.9/1000 and 1.1/1000 in the contacted population.
  • About one-half of the surgeries for benign neoplasms in compliant women were treated against the recommendation of the screening programme.
  • CONCLUSIONS: The implementation of the screening programme did not increase the incidence of treatment for benign neoplasms, and detected 50% more malignant neoplasms.
  • [MeSH-major] Breast Neoplasms / epidemiology. Mammography. Mass Screening. Patient Compliance / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007652.001).
  • [ISSN] 0969-1413
  • [Journal-full-title] Journal of medical screening
  • [ISO-abbreviation] J Med Screen
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Milot L, Guindi M, Gallinger S, Moulton CA, Brock KK, Dawson LA, Haider MA: MR imaging correlates of intratumoral tissue types within colorectal liver metastases: a high-spatial-resolution fresh ex vivo radiologic-pathologic correlation study. Radiology; 2010 Mar;254(3):747-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In seven consecutive patients undergoing hepatic resection for liver metastases (primary colorectal in six, breast mistaken for colorectal in one), the resected fresh ex vivo liver specimen was examined with T1-weighted (repetition time msec/echo time msec, 9/4.4-4.8) and T2-weighted (2500/90) MR imaging by using a voxel size of 0.47 x 0.7 x 2 mm.
  • This SI pattern is unusual for common benign liver lesions and may be helpful in the MR imaging diagnosis of colorectal liver metastases. (c) RSNA, 2010.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. In Vitro Techniques. Linear Models. Male. Middle Aged. Neoplasm Staging. Prospective Studies


12. Soares Leite D, Lima de Lima PD, Ferreira Leal M, Suchi Chen E, Casartelli C, de Arruda Cardoso Smith M, Rodríguez Burbano R: Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation. Clin Exp Med; 2006 Dec;6(4):166-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation.
  • Fibroadenoma (FA) is a benign breast tumour that occurs in about 25% of women.
  • Cytogenetic studies suggest that numerical chromosomal aberrations may contribute to tumorigenesis, but chromosomal instability is still poorly characterised in breast cancer.
  • The aim of this study was to investigate numerical alterations of chromosome 21 in 15 breast FAs.
  • Classical cytogenetics analysis showed that all cells were diploidies with modal number varying between 43 and 47 chromosomes, and clonal chromosome alterations in 46.7% of tumours.
  • The study of benign proliferations and comparison with chromosome alterations in their malignant counterparts should result in an understanding of the genes acting in cell proliferation alone and those that cause these cells to both undergo malignant transformation and become invasive.
  • [MeSH-major] Aneuploidy. Breast Neoplasms / genetics. Chromosomes, Human, Pair 21 / genetics. Fibroadenoma / genetics. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191108.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


13. Ławicki S, Szmitkowski M, Wojtukiewicz M: The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin Chim Acta; 2006 Sep;371(1-2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
  • BACKGROUND: In the present study, we investigated the plasma levels of M-CSF and commonly accepted tumor marker (antigen CA 15-3) in breast cancer patients in relation to the group with benign breast tumor and to the healthy controls.
  • Additionally, we compared the plasma level of M-CSF with the tumor stage of breast cancer and defined the diagnostic criteria: sensitivity, specificity, the positive and the negative predictive values.
  • METHODS: M-CSF and CA 15-3 were measured in 80 patients with breast cancer, 17 patients with benign breast tumor and in 30 healthy subjects.
  • RESULTS: There were statistically significant differences in the levels of circulating M-CSF and CA 15-3 in the breast cancer patients comparing to the group with benign breast tumor and to the control group.
  • The levels of M-CSF and CA 15-3 were also significantly higher in patients with more advanced tumor stage.
  • Statistically significant positive correlation was observed between the M-CSF and CA 15-3 levels.
  • The M-CSF and CA 15-3 diagnostic specificities were 95%.
  • We observed a higher range of the diagnostic sensitivity of M-CSF in more advanced breast tumor stage.
  • The M-CSF area under the ROC curve was larger (0.801) than the ROC area of CA 15-3 (0.785).
  • CONCLUSIONS: These results suggest that M-CSF is the good candidate for a breast cancer tumor marker.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Macrophage Colony-Stimulating Factor / blood. Mucin-1 / blood
  • [MeSH-minor] Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Reagent Kits, Diagnostic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631152.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Reagent Kits, Diagnostic; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


14. Roncella S, Ferro P, Franceschini MC, Bacigalupo B, Dessanti P, Sivori M, Carletti AM, Fontana V, Canessa PA, Pistillo MP, Fedeli F: Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin. Diagn Mol Pathol; 2010 Jun;19(2):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
  • As was reported that human mammaglobin (hMAM) may be expressed in malignant pleural effusions (PEs), we investigated the relevance of hMAM reverse-transcriptase polymerase chain reaction (RT-PCR) for their diagnosis and determination of primary origin.
  • Two hundred and twenty-eight malignant (132 male, 96 female) and 185 benign (132 male, 53 female) PEs were investigated.
  • Statistical analyses evaluated the diagnostic performance parameters in all PEs and in cytologically negative malignant PEs, the association between hMAM and benign or malignant status by the direct index of correlation [diagnostic odds ratio (DOR)], chi test, and P value (P).
  • In addition, the discriminative diagnostic power of hMAM expression, independently in breast cancer, lung cancer (LC), malignant mesothelioma (MM), and other cancers was evaluated.
  • In the entire patient population, hMAM was detected in 45.6% and 5.4% of malignant and benign PEs, respectively, in the male group in 41.7% and 4.5% and in the female group in 51.0% and 7.5% of malignant and benign PEs, respectively.
  • A statistically significant correlation between hMAM and malignancy was found in the entire population (DOR=14.68, P<0.001) and in the male (DOR=15.00, P<0.001) or female (DOR=12.77, P<0.001) groups. hMAM RT-PCR increased the diagnostic rate of malignant PEs as it allowed us to detect as malignant 32.1% of cytologically negative PEs.
  • In female patients the positivity of hMAM indicated with higher probability (50.8%) the origin of PEs from breast cancer but lower probability from LC (17%), MM (9.4%), or other cancers (15.1%), whereas in male patients it indicated with similar probability (about 40%) the origin from LC or MM.
  • Our results suggest that hMAM RT-PCR may provide information both in the diagnosis of PE and in the search for the primary site of neoplasia, either in male or female patients.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Neoplasm Proteins / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / etiology. Reverse Transcriptase Polymerase Chain Reaction / methods. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Male. Mammaglobin A. Middle Aged. United States. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502186.001).
  • [ISSN] 1533-4066
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


15. Swellam M, Arab LR, Bushnak HA: Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer. IUBMB Life; 2007 Jun;59(6):394-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer.
  • The aggressive biological behavior of invasive and metastatic cancer is considered to be the most insidious and life-threatening aspect for breast cancer patients.
  • It is mostly the result of changes in many molecular characteristics of tumor cells, including alterations in gene expression and the balance of proteolytic activity.
  • Markers were analyzed in 240 tissue samples categorized into 96 benign breast disease and 144 breast cancer patients.
  • Breast cancer patients were followed-up for three years.
  • Positive values for all investigated factors were significantly increased in breast cancer patients compared to benign ones.
  • Mean levels for all investigated factors were significantly correlated with lymph node and hormone receptor status, while MMP-2 and TIMP-2 were correlated with tumor grade (P < 0.05).
  • In Univariate analysis, positive MMP-2, MMP-2/TIMP-2, HER-2/neu overexpression, higher tumor grade, late clinical stages and positive lymph nodes status were significantly associated with relapse.
  • By multivariate analysis, all aforementioned factors apart from tumor grade were independent variables.
  • Thus, the investigated markers are constructive for biologic aggressiveness of breast cancer and MMP-2/TIMP-2 ratio might be a new significant marker in early diagnosis and estimate prognosis in breast cancer.
  • [MeSH-major] Breast Neoplasms. Matrix Metalloproteinase 2 / metabolism. Receptor, ErbB-2 / metabolism. Tissue Inhibitor of Metalloproteinase-2 / metabolism
  • [MeSH-minor] Adult. Biomarkers / metabolism. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Reproducibility of Results. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613170.001).
  • [ISSN] 1521-6543
  • [Journal-full-title] IUBMB life
  • [ISO-abbreviation] IUBMB Life
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


16. Giri D: Recurrent challenges in the evaluation of fibroepithelial lesions. Arch Pathol Lab Med; 2009 May;133(5):713-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The morphologic spectrum of mammary fibroepithelial lesions ranges from fibroadenoma, a common benign neoplasm, to phyllodes tumor, an uncommon lesion that can sometimes recur and metastasize.
  • OBJECTIVE: To focus on problems encountered in the diagnostic evaluation of fibroepithelial tumors, highlighting the diagnostically relevant morphologic features and providing an update on the immunohistochemical profile and genetic alterations of these rare neoplasms.
  • DATA SOURCES: A PubMed search of the English-language literature identified published reports on fibroepithelial lesions, with a special focus on phyllodes tumor.
  • CONCLUSIONS: The distinction between fibroadenoma and phyllodes tumor is usually not problematic, especially in excision specimens.
  • Morphologic predictors of local recurrence of phyllodes tumor include cellularity and cytologic atypia, mitotic activity, positive margins, infiltrative borders, fibroproliferative satellite nodules, and past history of fibroadenoma.
  • Predictors of distant metastasis include size, tumor necrosis, and stromal overgrowth.
  • Presently, molecular and immunohistochemical techniques play a limited role in the diagnosis of fibroepithelial lesions.
  • [MeSH-major] Breast Neoplasms / diagnosis. Fibroadenoma / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Gene Expression. Humans. Immunoenzyme Techniques. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415945.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 46
  •  go-up   go-down


17. Chen YW, Chuang YW, Lai YC, Hsieh JS, Liu GC, Hou MF: Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor? Ann Nucl Med; 2006 Jan;20(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is early dynamic lymphoscintigraphy for detection of sentinel lymph nodes always achievable in breast tumor?
  • OBJECTIVE: In this article, we will discuss the achievement of early dynamic lymphoscintigraphic protocol and compare detection of sentinel node between benign and malignant breast tumors, and whether pathologic factor is related or not.
  • The average age of patients was 47.6 +/- 9.8 years and all of them were clinically suspected of having breast cancer.
  • The average tumor was 2.1 +/- 1.1 cm in size.
  • All patients underwent surgery sixteen to twenty hours later and had a final pathological diagnosis.
  • From the summation image of dynamic study, identified axillary sentinel nodal activity was found as 80% in the group of benign breast tumor, but only 48% in the group of malignant breast tumor.
  • However, this short period of protocol is not always achievable to detect sentinel node, especially in the group with breast malignant lesions.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Breast Neoplasms / secondary. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Sentinel Lymph Node Biopsy / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485574.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


18. Abd El-Wahed MM: Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. J Egypt Natl Canc Inst; 2005 Sep;17(3):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features.
  • BACKGROUND AND PURPOSE: Maspin is an inhibitor of serine proteinases with tumor suppressor activity that is down-regulated in breast and prostate cancer, but overexpressed in pancreatic carcinoma.
  • The aim of the present study was to evaluate maspin expression in ovarian epithelial neoplasms and correlate its expression with some clinicopathologic parameters.
  • MATERIAL AND METHODS: Seventy eight paraffin embedded ovarian specimens from patients with ovarian epithelial neoplasms comprised the material of this study.
  • They included 18 benign, 14 low malignant potential (LMP) and 46 malignant epithelial ovarian neoplasms, in addition to seven specimens from normal ovarian tissues as a control.
  • RESULTS: Immunohistochemical study of maspin expression using streptavidin biotin immunoperoxidase method revealed that, normal ovarian surface epithelium did not express maspin as well as benign serous and mucinous ovarian epithelial neoplasm.
  • However, all benign Brenner ovarian tumors were maspin positive.
  • On the other hand, 57.14% of LMP tumors showed weak maspin expression and 63% of malignant ovarian epithelial tumors showed maspin expression with 39.1% over expression.
  • The two malignant Brenner tumors studied were maspin negative.
  • There was a trend for maspin expression with high grade, high stage, bilateral tumors and tumors with metastasis.
  • Tumors that showed maspin over-expression showed higher mitotic index (MI) (p=0.02).
  • Invasive cancers were more likely to have predominantly cytoplasmic staining compared to LMP tumors.
  • CONCLUSION: Maspin was expressed in a substantial proportion of ovarian tumors with poor prognostic parameters.
  • These results may offer new insights regarding the role of maspin in ovarian cancer that may also impact diagnosis and treatment strategies.
  • Moreover, variation in maspin expression between Brenner tumor and other epithelial surface ovarian tumors may indicate that the different histological types probably represent distinct disease entities and involve different molecular pathways.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Serine Proteinase Inhibitors / metabolism
  • [MeSH-minor] Adolescent. Adult. Brenner Tumor / metabolism. Brenner Tumor / pathology. CA-125 Antigen / analysis. Carcinoembryonic Antigen / analysis. Epithelium / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Ovary / metabolism. Serpins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799655.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


19. Wu J, Brinker DA, Haas M, Montgomery EA, Argani P: Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy. Int J Surg Pathol; 2005 Jan;13(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy.
  • Alveolar soft part sarcoma (ASPS) is a rare neoplasm that most commonly presents in the lower extremities.
  • To our knowledge, only 1 case of ASPS arising within the breast has previously been reported.
  • The patient was a 44-year-old woman who presented with a breast mass.
  • The cells labeled strongly for the histiocytic marker CD68, suggesting a benign macrophage-rich lesion.
  • The diagnosis of ASPS was confirmed by electron microscopy, which revealed characteristic membrane-bound rhomboidal crystals, as well as by nuclear labeling for TFE3 protein by immunohistochemistry.
  • [MeSH-major] Breast Neoplasms / pathology. DNA-Binding Proteins. Deoxycytidine / analogs & derivatives. Sarcoma / secondary. Soft Tissue Neoplasms / pathology. Transcription Factors. Xanthomatosis / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Antimetabolites, Antineoplastic / therapeutic use. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Biomarkers, Tumor / analysis. Cytoplasmic Vesicles / ultrastructure. Female. Humans. Microscopy, Electron, Transmission. Treatment Outcome

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735860.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA88843
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antimetabolites, Antineoplastic; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / DNA-Binding Proteins; 0 / TFE3 protein, human; 0 / Transcription Factors; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


20. Suga K, Kawakami Y, Hiyama A, Matsunaga N: Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan. Ann Nucl Med; 2009 Jun;23(4):399-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
  • OBJECTIVE: To evaluate the ability of dual-time point F-18-fluorodeoxy-glucose (FDG) PET/CT scans to differentiate FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer.
  • METHODS: A total of 64 FDG-avid recurrent lesions (local tumor recurrence or lymph node metastases) in 52 patients and 38 FDG-avid compromised benign lesions after surgery in 37 patients were included in the study.
  • RESULTS: The average early SUVmax, delayed SUVmax and DeltaSUVmax% were 4.9 +/- 2.6, 6.0 +/- 3.6 and 18.2% +/- 18.8 in FDG-avid recurrent lesions, and 2.1 +/- 0.8, 1.8 +/- 1.0 and -17.8% +/- 21.3 in FDG-avid benign lesions, respectively.
  • Delayed SUVmax was significantly increased compared with early SUVmax in recurrent lesions (P < 0.0001), while it was decreased in benign lesions (P < 0.0001).
  • All the three parameters in recurrent lesions were significantly higher than those in benign lesions (P < 0.0001).
  • CONCLUSIONS: This approach with SUVmax estimation appears to improve the differentiation between FDG-avid loco-regional recurrent of breast cancer and compromised benign lesions after surgery, since delayed scanning significantly enhances the difference in FDG uptake between these lesions.
  • [MeSH-major] Breast Neoplasms / surgery. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Positron-Emission Tomography. ROC Curve. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452249.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Roncella S, Ferro P, Bacigalupo B, Dessanti P, Pronzato P, Franceschini MC, Pratticò L, Carletti AM, Canessa PA, Fontana V, Fais F, Pistillo MP, Fedeli F: Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions. Diagn Mol Pathol; 2008 Mar;17(1):28-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions.
  • The present study investigates the diagnostic significance of human mammaglobin (hMAM) mRNA expression in pleural effusions (PE) from breast cancer (BC) patients.
  • Two hundred and fifty PE samples, including 32 from patients who had diagnosis of BC, 116 from patients with other cancers, and 102 from patients with benign diseases, were subjected to nested reverse-transcription polymerase chain reaction (RT-PCR) for hMAM, and the results were compared with conventional cytology. hMAM was found expressed in 76/250 (30.4%) total PE and in 23/28 (sensitivity of 82.1%) of the PE subgroup owing to metastasis from BC.
  • The specificity for hMAM detection method was 75.7%, whereas accuracy, positive predictive value, and negative predictive value were 76.4%, 30.3%, and 97.1%, respectively. hMAM was also detected in 46/116 (39.6%) PE specimens from other types of cancer and in 7/102 (6.8%) from benign diseases.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion, Malignant / diagnosis. Reverse Transcriptase Polymerase Chain Reaction. Uteroglobin / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Humans. Mammaglobin A. Middle Aged. RNA, Messenger / metabolism. Sensitivity and Specificity. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303409.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


22. Fuchsjaeger MH, Flöry D, Reiner CS, Rudas M, Riedl CC, Helbich TH: The negative predictive value of electrical impedance scanning in BI-RADS category IV breast lesions. Invest Radiol; 2005 Jul;40(7):478-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The negative predictive value of electrical impedance scanning in BI-RADS category IV breast lesions.
  • OBJECTIVES: We sought to prospectively assess the value of electrical impedance scanning (EIS) in discriminating benign from malignant lesions classified as BI-RADS category IV in mammography in comparison with ultrasound (US), with a special focus on negative prediction.
  • RESULTS: Histology proved 37 lesions malignant, 91 benign.
  • CONCLUSIONS: With a NPV of 97.1% of EIS in BI-RADS category IV breast lesions, a negative result in these lesions could be firm indication to manage them as BI-RADS-category III and refer patients for a 6-month short-interval follow-up rather than performing a biopsy.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Electric Impedance. Ultrasonography, Mammary
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973141.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Martínez-Galán J, Torres B, Del Moral R, Muñoz-Gámez JA, Martín-Oliva D, Villalobos M, Núñez MI, Luna Jde D, Oliver FJ, Ruiz de Almodóvar JM: Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther; 2008 Jun;7(6):958-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy.
  • The aim of the present study was to investigate the association between gene hypermethylation and main clinicopathological features of breast cancer, including diagnosis and treatment response.
  • A sensitive SYBR green methylation-specific PCR technique was used to analyze the utility of circulating DNA with CpG island hypermethylation of ESR1, APC, RARB, 14-3-3-sigma and E-cad gene promoter regions as breast cancer biomarkers.
  • Analyses were conducted of preoperative sera from 106 women with breast cancer, 34 with benign breast disease and 74 with no evidence of breast disease and of post-treatment sera from 60 of the breast cancer patients.
  • Mean serum values of methylated ESR1 and 14-3-3-sigma gene promoters significantly differed between breast cancer patients and healthy controls (p = 0.0112 for ESR1 and p = 0.0047 for 14-3-3-sigma).
  • When their results were combined, it was found that hypermethylation of these two genes differentiated between breast cancer patients and healthy controls (p < 0.0001) with a sensitivity of 81% (95% confidence interval: 72-88%) and specificity of 88% (95% CI: 78-94%).
  • Presence of methylated ESR1 in serum of breast cancer patients was associated with the ER negative phenotype (p = 0.0179).
  • Serum hypermethylation at ESR1 and 14-3-3-sigma loci was observed in cancer patients, in situ carcinoma and benign breast disease.
  • Preliminary clinical applications of this approach have revealed several shortcomings, including a frequent presence of methylated 14-3-3-sigma in sera from women with breast benign disease.
  • These findings cast some doubts on the utility for early cancer diagnosis of highly sensitive techniques to identify hypermethylation of specific gene promoters in DNA extracted from serum.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Estrogen Receptor alpha / metabolism. Exonucleases / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Case-Control Studies. DNA Methylation. DNA, Neoplasm / metabolism. Disease Progression. Exoribonucleases. Female. Humans. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Sensitivity and Specificity. Treatment Outcome


24. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group: Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci U S A; 2008 Sep 23;105(38):14533-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
  • Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
  • Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
  • Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Fibroadenoma / genetics. Fibroadenoma / metabolism. Mutation, Missense. Receptors, Prolactin / genetics. Receptors, Prolactin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Guide to Pharmacology. gene/protein/disease-specific - Prolactin-releasing peptide receptor - overview and references .
  • Guide to Pharmacology. gene/protein/disease-specific - PrRP receptor - data and references .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):665-71 [14696092.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4056-66 [16809439.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Acta Obstet Gynecol Scand. 1987;66(6):483-8 [3321867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4031-5 [7537382.001]
  • [Cites] Mol Endocrinol. 1996 Jan;10(1):45-56 [8838144.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29707-14 [8939904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):989-1008 [17138649.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):841-4 [17299388.001]
  • [Cites] BMC Med Genet. 2007;8:72 [18053149.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Front Biosci. 2000 Mar 1;5:D343-52 [10704433.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3826-32 [11502819.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):49-66 [12160086.001]
  • [Cites] Endocrine. 2003 Feb-Mar;20(1-2):177-90 [12668884.001]
  • [Cites] Recent Prog Horm Res. 2003;58:297-323 [12795425.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):35988-99 [12824168.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10024-34 [10187780.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):275-85 [16034013.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):555-62 [16278261.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1513-9 [16434456.001]
  • [Cites] J Endocrinol. 2006 Aug;190(2):271-85 [16899561.001]
  • [Cites] Biol Reprod. 2004 Mar;70(3):718-28 [14613905.001]
  • (PMID = 18779591.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Receptors, Prolactin; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • [Other-IDs] NLM/ PMC2567233
  • [Investigator] Bachelot A; Belaroussi B; Bensimhon J; Berdah J; Blin MJ; Boudinet A; Brethon B; Bricaire C; Caby J; Caillaud G; Carel JC; Chabbert-Buffet N; Charitanski H; Chretien C; Clough K; Courtillot C; Delattre G; Denys I; Desthieux-Ngo K; Detoeuf M; Dhainault C; Duflos C; Fiori O; Genestie C; Gibaud G; Gompel A; Gracia C; Grimard A; Hofman C; Hofman H; Kuttenn F; Laki F; Lanty C; Lefranc JP; Le Frere-Belda MA; Leger D; Martinez F; May A; Meng L; Nos C; Pelletier D; Perrin A; Plu-Bureau G; Raccah-Tebbeca B; Saiovici JC; Salmon R; Sibout M; Sigal-Zafrani B; Thalabard JC; Thibaud E; Thoury A; Touraine P; Triana-Rabi KB; Uzan S; Viriot J; Yacoub S
  •  go-up   go-down


25. Zalinski S, Goumard C, Scatton O, Terris B, Plantier F, Dupin N, Soubrane O: Liver recurrence of a subcutaneous temporal hemangiopericytoma: the index case. J Gastrointest Surg; 2009 Jun;13(6):1155-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Hemangiopericytoma is an uncommon soft tissue vascular neoplasm.
  • Its natural history is mostly benign, but recurrences may occur and determining if these late-discovered tumors are distant metastases or synchronous slow and silent-growing locations is sometimes challenging.
  • The histopathological diagnosis and definition of hemangiopericytoma is based on its distinction with solitary fibrous tumors.
  • [MeSH-major] Hemangiopericytoma / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Breast Neoplasms / pathology. Female. Hepatectomy. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Surg. 1991 Jul;21(4):462-5 [1960907.001]
  • [Cites] Cancer Imaging. 2006 Jun 08;6:56-9 [16766270.001]
  • [Cites] Cancer. 1999 Aug 25;87(4):190-5 [10455206.001]
  • [Cites] Hum Pathol. 1976 Jan;7(1):61-82 [1244311.001]
  • [Cites] Histopathology. 2006 Jan;48(1):63-74 [16359538.001]
  • [Cites] Acta Cytol. 2003 Mar-Apr;47(2):281-6 [12685202.001]
  • [Cites] Semin Diagn Pathol. 1995 Aug;12(3):221-32 [8545589.001]
  • [Cites] J Ultrasound Med. 2008 Apr;27(4):667-71 [18359915.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Jun;29(6):409-11 [17551404.001]
  • [Cites] Hum Pathol. 1998 Jun;29(6):636-40 [9635686.001]
  • [Cites] Cancer. 1975 Dec;36(6):2232-44 [1203874.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1413-8 [15668900.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):897-907; discussion 907-8 [17122615.001]
  • [Cites] Transplantation. 1999 Feb 15;67(3):488-9 [10030302.001]
  • [Cites] World J Gastroenterol. 2005 Jul 21;11(27):4281-4 [16015707.001]
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):86-91 [9544821.001]
  • [Cites] Ann Surg. 1942 Jul;116(1):26-33 [17858068.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Apr;28(4):237-40 [16679922.001]
  • [Cites] J Am Coll Surg. 2003 Oct;197(4):687-8 [14522337.001]
  • [Cites] Ann Surg Oncol. 1998 Jun;5(4):350-5 [9641457.001]
  • [Cites] Am J Otolaryngol. 2000 Jul-Aug;21(4):238-43 [10937909.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):514-22 [2797389.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):884-5 [1818550.001]
  • [Cites] Cancer. 1999 May 15;85(10):2245-8 [10326704.001]
  • [Cites] Prog Urol. 2003 Jun;13(3):498-501 [12940206.001]
  • [Cites] Surg Today. 1993;23(7):644-8 [8369618.001]
  • [Cites] Ann Surg. 1960 Nov;152:804-8 [13716736.001]
  • (PMID = 19148704.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M, Choolani M: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer; 2010;10:64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.
  • Factors, especially those associated with cell-cycle genes, affecting the genesis and tumour progression for ovarian cancer are largely unknown.
  • Our hypothesis was supported by our tissue array experiments that showed E2F5 expression only in OEC samples but not in normal and benign tissues, and by significantly positively biased expression in serum samples done using western blotting studies.
  • E2F5 used in different combinations with CA125 for distinguishing malignant cyst from benign cyst shows that the presence of CA125 or E2F5 increases sensitivity of OEC detection to 97.9% (an increase from 87.5% if only CA125 is used) and, more importantly, the presence of both CA125 and E2F5 increases specificity of OEC to 72.5% (an increase from 55% if only CA125 is used).
  • Furthermore, detection of malignancy status in 86 cases (38 benign, 48 early and late OEC) shows that the use of E2F5 status in combination with other clinical characteristics allows for an improved detection of malignant cases with sensitivity, specificity, F-measure and accuracy of 97.92%, 97.37%, 97.92% and 97.67%, respectively.
  • CONCLUSIONS: Overall, our findings, in addition to opening a realistic possibility for improved OEC diagnosis, provide an indirect evidence that a cell-cycle regulatory protein E2F5 might play a significant role in OEC pathogenesis.
  • [MeSH-major] E2F5 Transcription Factor / physiology. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor / metabolism. CA-125 Antigen / biosynthesis. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Reproducibility of Results. Sensitivity and Specificity


27. Ravindra S, Suguna BV: Cytomorphology of tubular adenoma breast--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):267-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of tubular adenoma breast--a case report.
  • Tubular adenoma a 'pure adenoma' is a benign neoplasm of breast presenting clinically like fibroadenoma.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibrocystic Breast Disease / pathology. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933735.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


28. Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C: Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J BUON; 2009 Jul-Sep;14(3):463-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
  • PURPOSE: In this study we evaluated the clinical usefulness of serum pro-I collagen peptide (PICP) and I collagen telopeptide (ICTP) as indicators of early bone metastases in patients with breast (BC), lung (LC), urinary bladder (UBC) and prostate cancer (PC).
  • ICTP and CA 15-3 were the most reliable markers for early diagnosis of bone metastases in BC.
  • Furthermore, PICP and PSA levels were significantly higher in patients with PC and bone metastases in comparison to patients with benign prostate hyperplasia (BPH) (p <0.0001) or in patients with PC without bone metastases (p <0.0005 for PICP and p <0.0001 for PSA).
  • CONCLUSION: ICTP and CA 15-3 are the most reliable markers for early diagnosis of bone metastases in BC patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / metabolism
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / pathology. Carcinoembryonic Antigen / metabolism. Female. Humans. Immunoradiometric Assay. Lung Neoplasms / pathology. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Metastasis. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / pathology. Sensitivity and Specificity. Tomography, Emission-Computed. Urinary Bladder Neoplasms / pathology


29. Sandhya B, Babu V, Parthasarathy G, Kate V, Ananthakrishnan N, Krishnan R: Primary leiomyosarcoma of the breast: A case report and review of literature. Indian J Surg; 2010 Jul;72(Suppl 1):286-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the breast: A case report and review of literature.
  • Leiomyosarcomas of the breast are rare tumours.
  • We describe herein a case of primary leiomyosarcoma of the breast in a 54-year-old woman whose preoperative clinical and cytological findings indicated a benign breast tumour.
  • Histopathological examination of the mastectomy specimen suggested a diagnosis of leiomyosarcoma, which was subsequently confirmed by immunohistochemical analysis.
  • Primary leiomyosarcoma of the breast is very rare and is difficult to diagnose preoperatively as it needs immuno-histochemical staining.
  • It is necessary to excise the tumour with sufficient margins to prevent local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1997;27(11):1082-5 [9413066.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):151-3 [11458280.001]
  • [Cites] Surg Today. 2002;32(8):716-9 [12181723.001]
  • [Cites] Arch Gynecol Obstet. 2003 Feb;267(4):233-5 [12592426.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):494-6 [14616945.001]
  • [Cites] Diagn Cytopathol. 2003 Sep;29(3):172-8 [12951688.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):783-6 [14526679.001]
  • (PMID = 23133273.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451846
  • [Keywords] NOTNLM ; Breast / Phyllodes Sandhya / Stromal tumours
  •  go-up   go-down


30. Iyengar P, Cody HS 3rd, Brogi E: Pleomorphic adenoma of the breast: case report and review of the literature. Diagn Cytopathol; 2005 Dec;33(6):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma of the breast: case report and review of the literature.
  • Pleomorphic adenoma of the breast (PAB) is a very rare neoplasm.
  • Cytologic diagnosis of this lesion can be very challenging, especially when limited sampling is available.
  • The differential diagnosis of PAB includes metaplastic carcinoma.
  • On cytologic material, fibroadenoma and phyllodes tumor should also be considered within the differential diagnosis.
  • Correct identification of this benign mammary neoplasm is important to avoid unnecessarily aggressive treatment.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Diagnostic Errors. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 16299746.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Gao P, Zhou GY, Zhang QH, Xiang L, Ma C, Yu HP, Yu F: [Expression of mucin 1 and tumor invasiveness in breast carcinoma]. Zhonghua Yi Xue Za Zhi; 2005 Feb 16;85(6):381-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of mucin 1 and tumor invasiveness in breast carcinoma].
  • OBJECTIVE: To study the relationship of abnormal expression of mucin 1 with the invasiveness of breast carcinoma cells.
  • METHODS: Immunohistochemistry was used to detect the protein expression of mucin 1 in 5 specimens of juxta-cancerous normal tissues, 20 specimens of benign breast tumors, 35 specimens of early breast carcinoma, 22 specimens of infiltrating cancerous tissues, and 20 specimens of lymph node foci with metastatic breast carcinoma.
  • Human breast cancer cells of the line MCF-7 were cultured and transfected with antisense oligodeoxynucleotide (ASODN) of mucin 1.
  • RESULTS: Top membrane positive expression of mucin 1 was observed in the normal breast tissues and breast benign tumors and whole membrane positive expression of mucin 1 was observed in the 30 of the 35 specimens of early breast carcinoma, 18 of the 22 specimens of breast infiltrating carcinoma, and 17 of the 20 specimens of lymph node metastatic tissues.
  • The mRNA and protein expressions of mucin 1 in the breast carcinoma cells treated with ASODN of mucin 1 were significantly decreased (both P < 0.05).
  • The invasiveness of breast carcinoma cells can be inhibited by the ASODN complementary to the start site of mucin1 mRNA.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Mucins / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor. Female. Humans. Neoplasm Invasiveness. Oligodeoxyribonucleotides, Antisense / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Transfection. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854526.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / RNA, Messenger
  •  go-up   go-down


32. Ko E, Han W, Lee JW, Cho J, Kim EK, Jung SY, Kang MJ, Moon WK, Park IA, Kim SW, Kim KS, Lee ES, Min KH, Kim SW, Noh DY: Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy. Breast Cancer Res Treat; 2008 Nov;112(1):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was to determine factors that predict under-evaluation of malignancy in patients diagnosed with atypical ductal hyperplasia (ADH) at ultrasound-guided core needle biopsy (CNB), and to develop a prediction algorithm for scoring the possibility of a diagnosis upgrade to malignancy based on clinical, radiological and pathological factors.
  • This system was able to identify a subset of patients with lesions likely to be benign, indicating that imaging follow-up rather than surgical excision may be appropriate.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Diagnostic Imaging. Hyperplasia / pathology. Hyperplasia / ultrasonography
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Female. Humans. Mammography. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060577.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


33. Ye YB, Zhou ZF, Chen Q, Li JY, Chen X, Huang WW: [The roles of soluble MICA in immune escape of breast tumor]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Sep;24(9):904-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The roles of soluble MICA in immune escape of breast tumor].
  • AIM: To determine the expression of soluble MICA (sMICA) in serum of patients with breast tumor, and explore the roles of sMICA in immune escape.
  • The cytotoxicity of NK cells to breast cancer cells was observed with MTT assay.
  • RESULTS: sMICA was not detected in the serum of healthy person, but(76.8+/-22.3) ng/L in breast benign tumor patients and (205.4+/-71.3) ng/L in breast malignant tumor patients.
  • There was positive correlation between sMICA levels and breast cancer stage.
  • IL-15 up-regulated the expression of NKG2D on NK cells and increased NK cells cytotoxicity to breast cancer cells.
  • CONCLUSION: sMICA level is positive correlated with breast cancer TNM stage. sMICA reduced the expression of NKG2D, impaired NK-mediated immune surveillance and led to immune escape of breast tumor.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / immunology. Histocompatibility Antigens Class I / blood
  • [MeSH-minor] Cells, Cultured. Cytotoxicity, Immunologic. Female. Humans. Killer Cells, Natural / immunology. Neoplasm Staging. Solubility

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782524.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / MHC class I-related chain A
  •  go-up   go-down


34. Navas Cañete A, Olcoz Monreal FJ, García Laborda E, Pérez Aznar JM: [Pseudoangiomatous stromal hyperplasia: magnetic resonance findings in two cases]. Radiologia; 2007 Jul-Aug;49(4):275-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hiperplasia pseudoangiomatosa estromal: hallazgos en resonancia magnética de dos casos.
  • Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast tumor of uncertain etiology, although marked hormonal influence clearly plays a role in this disease.
  • The differential diagnosis is important because this is an uncommon lesion that can simulate malignant lesions both at clinical and radiological examination, and even the histological results can be confusing.
  • [MeSH-major] Breast / pathology. Breast Diseases / diagnosis. Magnetic Resonance Imaging


35. Liebhardt S, Ditsch N, Nieuwland R, Rank A, Jeschke U, Von Koch F, Friese K, Toth B: CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients. Anticancer Res; 2010 May;30(5):1707-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients.
  • BACKGROUND: This is the first prospective case-control study that evaluates the expression of tumour-specific antigens on circulating microparticles (MP) in breast cancer patients and in women with benign breast tumour.
  • MATERIALS AND METHODS: MP were determined by flow cytometry in patients with breast cancer (n=34; T1 (n=19) and T2 (n=15)) and women with benign breast tumour (n=19).
  • RESULTS: Patients with lymph node metastases (N1, n=9) showed significantly higher numbers of annexin V(+) MP (p=0.042), CD66(+) MP (p=0.045), BCRP1(+) MP (breast cancer resistance protein) (p=0.025) and Hsp27(+) MP (p=0.034) than controls.
  • CONCLUSION: Significant differences are present between breast cancer patients with lymph node metastases and controls concerning annexin V-, CD66-, BCRP1- and Hsp27-positive MP.
  • To specify the role of these MP subpopulations in breast cancer progression, further studies enrolling larger patient groups are part of ongoing research.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Breast Neoplasms / metabolism. Carcinoembryonic Antigen / metabolism. Cell-Derived Microparticles. HSP27 Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Receptor, ErbB-2 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592365.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Annexin A5; 0 / Carcinoembryonic Antigen; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Neoplasm Proteins; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


36. Kunz U, Friedrich T: [Malignant fibrous histiocytoma. Clinical meaning of a rare entity]. Praxis (Bern 1994); 2007 Apr 25;96(17):681-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Das maligne fibröse Histiozytom der Mamma: Klinische Bedeutung einer seltenen Diagnose.
  • Less than 1% of primary malignant breast tumours are sarcomas.
  • There is an increase of reported cases of sarcoma of the breast after organ-conserving therapies of breast carcinoma and postoperative irradiation.
  • Even if MFH of the breast is very rare, the incidence rate is likely to increase with the rise of organ-conserving therapy of breast carcinoma.
  • MFH should be included in the differential diagnosis in cases of large tumour diameters, rapidly progressive tumour growth and absence of axillary lymph nodes or distant metastasis.
  • The report deals with a 90-year-old patient with exulcerated MFH of the left breast.
  • [MeSH-major] Breast Neoplasms. Histiocytoma, Benign Fibrous
  • [MeSH-minor] Aged. Aged, 80 and over. Breast / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymph Node Excision. Neoplasm Recurrence, Local / surgery. Time Factors. Treatment Outcome. Wound Healing

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491198.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


37. Aranda C, Sotelo M, Torres A, Zárate M: [Phyllodes tumor and pregnancy. A report of a case]. Ginecol Obstet Mex; 2005 Jul;73(7):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumor and pregnancy. A report of a case].
  • [Transliterated title] Tumor phyllodes y embarazo. Reporte de un caso.
  • Phyllodes tumor is a rare breast fibroepithelial neoplasm of the breast, predominant in females (0.3 to 0.5%).
  • Phyllodes tumor during pregnancy grows fast and its size is relatively big.
  • These tumors can be classified as benign, malignant or neighboring.
  • A 32-year-old patient at 23.4 week of gestation was admitted in the National Institute of Perinatology with a rapidly growing mass in the right breast; diagnosis confirmed by ultrasound study reporting echoic images on right breast, 10 x 10 cm the greatest and 3x3 cm the smallest.
  • A simple mastectomy was performed at the 26.6 week of gestation on the right breast.
  • A possible phyllodes tumour in the right breast was observed during surgery, weight 9.6 pounds, with partial infiltration to major pectoral muscle.
  • Pathology reported a benign phyllodes tumor in the right breast, with surgical borders free of tumor.
  • Phyllodes tumor is rare and can occur during pregnancy.
  • It is unknown if the tumor is hormone-dependent.
  • The growth of a tumor on a subsequent pregnancy is not necessarily associated with recurrency or with a new disorder on the patient, who has had a complete excision.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor. Pregnancy Complications, Neoplastic


38. Fiorucci F, Conti V, Lucantoni G, Patrizi A, Fiorucci C, Giannunzio G, Di Michele L: Sarcoidosis of the breast: a rare case report and a review. Eur Rev Med Pharmacol Sci; 2006 Mar-Apr;10(2):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoidosis of the breast: a rare case report and a review.
  • Sarcoidosis is an idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis.
  • Breast involvement is extremely rare, but, when present, it could be confused with a benign or, more important, a malignant neoplasm.
  • We have reported a case of sarcoidosis of the breast in a 51 years old woman with systemic manifestations of sarcoidosis (arthralgias and uveitis) associated with a breast mass and with a clinical history of fibrocystic mastopathy.
  • A chest X-ray and a Computed Tomography (CT), with raised serum levels of Angiotensin Converting Enzyme (ACE), were compatible with a diagnosis of sarcoidosis.
  • The mammography and ultrasonogram showed a solitary little nodular lesion localized in the breast.
  • A breast cancer in a patient with sarcoidosis?
  • To answer this question, the patient performed breast surgery under general anaesthesia and bioptic microscopic examination showed a typical sarcoid granuloma.
  • [MeSH-major] Breast Diseases / diagnosis. Sarcoidosis / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Tomography, X-Ray Computed. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16705947.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 6
  •  go-up   go-down


39. Braendle W, Kuhl H, Mueck A, Birkhäuser M, Thaler C, Kiesel L, Neulen J: [Does hormonal contraception increase the risk for tumors?]. Ther Umsch; 2009 Feb;66(2):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Does hormonal contraception increase the risk for tumors?].
  • A non-contraceptive benefit of oral hormonal contraceptives (OC) is a diminished risk for certain benign as well as malignant tumours, such as benign breast tumours, uterine fibroids and ovarian cysts.
  • Modern data do not suggest an increased risk for breast carcinoma in OC users.
  • [MeSH-major] Contraceptives, Oral, Hormonal / adverse effects. Neoplasms / chemically induced
  • [MeSH-minor] Adult. Age Factors. Case-Control Studies. Female. Genital Neoplasms, Female / chemically induced. Genital Neoplasms, Female / genetics. Humans. Long-Term Care. Middle Aged. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180433.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal
  • [Number-of-references] 47
  •  go-up   go-down


40. Bhargav PR, Mishra A, Agarwal G, Agarwal A, Verma AK, Mishra SK: Phyllodes tumour of the breast: clinicopathological analysis of recurrent vs. non-recurrent cases. Asian J Surg; 2009 Oct;32(4):224-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumour of the breast: clinicopathological analysis of recurrent vs. non-recurrent cases.
  • BACKGROUND: The aim of this study was to present our experience of dealing with patients with phyllodes tumours (PT) and to correlate the risk of local recurrence with different clinicopathological factors.
  • Various clinicopathological features were compared between patients who suffered from recurrent tumours to those not experiencing any recurrence.
  • The mean tumour diameter was 10.5 +/- 5 cm.
  • Preoperative diagnosis with fine needle aspiration cytology could be made in 72% of cases.
  • The histology report was benign, borderline and malignant PT in 28%, 20% and 52% of cases respectively.
  • Recurrent tumours were observed in 36% of patients and 16% experienced more than one recurrence.
  • However, when WLE was performed for recurrent tumours, 50% of patients suffered from recurrence.
  • CONCLUSION: WLE seems to be the initial procedure of choice for all PTs, and mastectomy for recurrent tumours.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892625.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


41. Ahmed IA, Pusch CM, Hamed T, Rashad H, Idris A, El-Fadle AA, Blin N: Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. Cancer Genet Cytogenet; 2010 Jun;199(2):96-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
  • Novel strategies for early detection of breast cancer, the most common and second most lethal cancer in women, are urgently needed.
  • Silencing tumor suppressor genes via DNA methylation has established hypermethylation as one of the most frequent molecular alterations that may initiate and drive many types of human neoplasia including breast cancer.
  • Detecting such epigenetic changes in DNA derived not only from tumor tissue, but also from bodily fluids, may be a promising target for the molecular analysis of cancer.
  • In this study we examined serum, a readily accessible bodily fluid known to contain neoplastic DNA, from individuals with breast carcinoma.
  • Using sensitive methylation-specific polymerase chain reaction, we searched for aberrant promoter hypermethylation of two normally nonmethylated genes: RAS association domain family member 1A (RASSF1A) and death-associated protein kinase 1 (DAPK1) in 26 patients with breast cancer, 16 patients with benign breast diseases, and 12 age-matched healthy controls.
  • Hypermethylation of at least one gene was detected in 25/26 (96%) cancer patients, in 7/16 (43%) cases with benign breast diseases, and only 1/12 (8%) control subjects.
  • Furthermore, methylation of both genes was found to be associated with ductal type of breast carcinoma.
  • These findings, if confirmed in studies of extended cohorts, may lead to useful clinical application in early diagnosis of breast cancer and better management of the neoplastic disease.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Breast Neoplasms / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. DNA Methylation. DNA, Neoplasm / genetics. Promoter Regions, Genetic / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Death-Associated Protein Kinases. Epigenesis, Genetic. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasms / genetics. Neoplasms / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471512.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / DAPK1 protein, human; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


42. Dragoumis DM, Assimaki AS, Tsiftsoglou AP: Solid variant of a pure intracystic papillary carcinoma of the breast: case report. Eur J Gynaecol Oncol; 2008;29(5):545-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid variant of a pure intracystic papillary carcinoma of the breast: case report.
  • Intracystic papillary carcinoma (IPC) of the breast is an uncommon malignant breast neoplasm and usually occurs in advanced age.
  • It is characterized by a more benign behavior and a subsequent higher survival rate.
  • We describe such a case of a 58-year-old female, who displayed a gradually growing tumor of the right breast.
  • Mammography, breast ultrasonography and fine needle aspiration cytology failed to obtain a definite diagnosis.
  • Based on the preoperative clinical identification of right axillary lymphadenopathy, the patient eventually underwent segmental resection of the right breast and right axillary nodal dissection.
  • As regards the histological findings, the neoplasm corresponded to a pure intracystic papillary carcinoma of the solid variant.
  • IPC represents a breast tumor with papillary differentiation growing inside a cyst, and excisional biopsy is often necessary to confirm the disease.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Breast Cyst / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051833.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


43. Varazashvili Varazi LM, Osmanova VR, Barkadze KI: [Study of serum levels of magnesium in the patients with malignant tumors]. Georgian Med News; 2006 Jul;(136):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of serum levels of magnesium in the patients with malignant tumors].
  • The main goal of the study was the evaluation of serum levels of magnesium in the practically healthy persons (control group), the patients with different malignant tumors (abdominal, pulmonary, uterus, breast, esophagus, rectum), as well as benign tumors of the breast/the uterus and the inflammatory pulmonary diseases.
  • It has been found that, in comparison with norm (23.9 mkg/ml), there is statistically significant increase in serum mean levels of Mg in the patients with malignant tumors of almost all sites investigated.
  • Abdominal/breast and lung malignant tumors are exclusive from this point of view: we have found that Mg content is near the normal mean levels in the former cases (24.7 mkg/ml and 25.3 mkg/ml, respectively) and below the average normal value in lung malignant tumors (20.5 mkg/ml).
  • It has been ascertained that there is no significant difference between the serum average levels of Mg in the control group and in the patients with pulmonary inflammatory diseases, as well as between the Mg-content in practically health persons and in those with breast benign tumors.
  • Thus, assessment of serum Mg levels seems to be useful in differential diagnosis in oncopulmonary and oncomammology clinics.
  • [MeSH-major] Biomarkers, Tumor / blood. Magnesium / blood. Neoplasms / blood
  • [MeSH-minor] Diagnosis, Differential. Humans. Prognosis

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905841.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; I38ZP9992A / Magnesium
  • [Number-of-references] 14
  •  go-up   go-down


44. Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Dürst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ: Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res; 2006 Jul 1;12(13):3950-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
  • PURPOSE: The aim of the present study was to identify human genes that might prove useful in the diagnosis and therapy of primary breast cancer.
  • EXPERIMENTAL DESIGN: Twenty-four matched pairs of invasive ductal breast cancer and corresponding benign breast tissue were investigated by a combination of laser microdissection and gene expression profiling.
  • Differential expression of candidate genes was validated by dot blot analysis of cDNA in 50 pairs of matching benign and malignant breast tissue.
  • Cellular expression of candidate genes was further validated by RNA in situ hybridization, quantitative reverse transcription-PCR, and immunohistochemistry using tissue microarray analysis of 272 nonselected breast cancers.
  • Dot blot analysis reduced the number of up-regulated genes to 15 candidate genes that showed at least a 2-fold overexpression in >15 of 50 (30%) tumor/normal pairs.
  • PPAPDC1A and KPNA2 RNA was up-regulated (fold change >2) in 84% and 32% of analyzed tumor/normal pairs, respectively.
  • CONCLUSIONS: Gene expression profiling of laser-microdissected breast cancer tissue revealed novel genes that may represent potential molecular targets for breast cancer therapy and prediction of outcome.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms. Carcinoma, Ductal, Breast. Gene Expression Profiling. Lasers. Microdissection / methods. alpha Karyopherins / genetics
  • [MeSH-minor] Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Staging. Phosphatidate Phosphatase / genetics. Prognosis. RNA / genetics. Regression Analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Sulfotransferases / genetics. Survival Rate. Tissue Array Analysis / methods. Up-Regulation / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818692.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha Karyopherins; 0 / karyopherin alpha 2; 63231-63-0 / RNA; EC 2.8.2.- / SULF1 protein, human; EC 2.8.2.- / Sulfotransferases; EC 3.1.3.- / lipid phosphate phosphatase; EC 3.1.3.4 / Phosphatidate Phosphatase
  •  go-up   go-down


45. Pieta B, Opala T, Wilczak M, Grodecka-Gazdecka S, Kramer L, Samulak D, Wieznowska-Maczyńska K: Past obstetric history and risk of malignant breast neoplasms. Eur J Gynaecol Oncol; 2008;29(4):374-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Past obstetric history and risk of malignant breast neoplasms.
  • Many studies indicate hormonal disorders as a crucial reason for breast pathology.
  • They are also probably responsible for the development of benign neoplasms and play a role in the origin and development of breast carcinoma.
  • Although the mammary gland is under the influence of many steroid and peptide hormones such as thyroid hormones, prolactin, growth hormone, glucocorticosteroids, it is estrogen that plays an important role in the development of breast cancer.
  • The purpose of the study was to analyze the obstetrical past of patients and the potential influence on the risk of developing malignant breast neoplasms.
  • The participants in the study were healthy women with no changes in mammary glands (control group) and women with diagnosed malignant or benign breast neoplasms (study group).
  • Hormonal disorders in childhood and puberty symptoms of early menarche play a crucial role in increasing the risk of malignant breast neoplasms.
  • In women who experienced one or more miscarriages the risk of malignant breast neoplasms is significantly increased.
  • On the basis of our study we calculated the odds ratio (OR) of malignant breast neoplasms among women who during lactation experienced problems needing medical intervention (OR = 2.25; 95% CI, 1.20-4.19) in comparison to women who experienced no problems).
  • [MeSH-major] Breast Neoplasms / epidemiology. Reproductive History
  • [MeSH-minor] Adult. Aged. Breast Diseases. Case-Control Studies. Confidence Intervals. Estrogens. Female. Humans. Middle Aged. Odds Ratio. Poland / epidemiology. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18714573.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogens
  •  go-up   go-down


46. Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N: Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am J Surg Pathol; 2008 Apr;32(4):544-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microglandular adenosis (MGA) of the breast is widely known as a benign lesion that can mimic invasive carcinoma.
  • Anderson Cancer Center between 1983 and 2007 that had a diagnosis of MGA.
  • Staining indices for the cell cycle markers p53 and Ki-67 were used to compare the 3 tumor categories.
  • Additional staining for other tumor markers [estrogen and progesterone receptors, HER2, epidermal growth factor receptor (EGFR), c-kit, CK5/6, and CK18] were performed.
  • Patient demographics, tumor radiologic features, and clinical follow-up data were collected for all cases.
  • All tumors had strong and diffuse CK8/18 and EGFR expression but no estrogen receptor, progesterone receptor, HER2 (ie, triple negative), or CK5/6 expression.
  • Although 11 tumors were only included in our study, 64% of the tumors were carcinomas arising in MGA.
  • Although all the MGACA cases were triple negative and express EGFR (basal-like features), all the cases in our study showed a luminal type of differentiation by CK8/18 expression, indicating that MGACA may not fit well into the current proposed molecular classification of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology. Fibrocystic Breast Disease / pathology. Immunohistochemistry. Precancerous Conditions / pathology
  • [MeSH-minor] Actins / analysis. Adult. Aged. Carcinoma in Situ / pathology. Diagnosis, Differential. Diagnostic Errors / prevention & control. Disease Progression. Female. Humans. Keratins / analysis. Ki-67 Antigen / analysis. Mastectomy. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-kit / analysis. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. S100 Proteins / analysis. Texas. Time Factors. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300793.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / S100 Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


47. Yao C, Wang SM, Xie D, Wu HX, Chen DY, Lin Y: [The relationship between expression of interleukin-8 and prognosis of breast cancer]. Zhonghua Wai Ke Za Zhi; 2006 Jul 1;44(13):900-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The relationship between expression of interleukin-8 and prognosis of breast cancer].
  • OBJECTIVE: To investigate the expression of interleukin-8 (IL-8) and its prognostic significance in breast cancer.
  • METHODS: Expression of IL-8 in 113 breast cancers, 19 breast benign tumors and 20 breast normal tissues was examined by tissue microarray using immunohistochemistry, and the association of IL-8 expression with patient's clinico-pathological characteristics and prognosis was further analyzed.
  • RESULTS: The positive rate of IL-8 expression in breast cancer was 27.4%, which was significantly higher than that in benign tumor and normal tissue of breast (P = 0.002).
  • CONCLUSIONS: IL-8 might be a poor prognostic factor for human breast cancer, and also might be a novel molecular marker to predicate the occurrence and progression of breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Interleukin-8 / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067482.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


48. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK: 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope; 2005 Jun;115(6):1074-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate the prevalence of incidental thyroid F-fluorodeoxyglucose (FDG) uptake in positron emission tomogram (PET) scan for evaluation in cancer patients and the role of standard uptake value (SUV) measurement in differentiation of thyroid malignancy from benign disease.
  • Cytologic diagnosis was available in 32 of 45 focal thyroid FDG uptakes.
  • In 16 (50%) patients, the tumor was found to be malignant; 14 were papillary thyroid carcinoma (surgically confirmed in 7 cases), 2 were metastatic tumor from breast and esophagus.
  • Sixteen were cytologically diagnosed as follicular cell lesions: follicular neoplasm (n = 2), nodular hyperplasia (n = 7), indeterminate follicular lesion (n = 7).
  • There was no significant difference in maximum SUV between benign and malignant nodules.
  • From 45 patients with diffuse thyroid FDG uptake, presumptive diagnosis of chronic thyroiditis was possible in 34 patients by clinical and laboratory findings.
  • CONCLUSION: Our data suggest that a cytologic diagnosis of focal thyroid FDG-PET incidentaloma regardless of SUV is mandatory considering the very high prevalence of thyroid malignancy.
  • [MeSH-major] Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Thyroid Gland / radionuclide imaging. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radionuclide imaging. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Thyroid Nodule / radionuclide imaging. Thyroiditis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933524.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


49. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer; 2006 May 22;94(10):1492-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
  • Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in blood plasma DNA.
  • Concentration of cirDNA and methylation of RARbeta2, RASSF1A and HIC-1 gene promoters were investigated in cell-free and cell-surface-bound fractions from healthy donors, patients with breast cancer, and patients with breast fibroadenoma.
  • Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surface-bound fractions.
  • Analysis of RARbeta2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women.
  • Results of the study indicate that methylation-specific PCR of RARbeta2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. DNA-Binding Proteins / genetics. Fibroadenoma / blood. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:5-7 [10818586.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6 [11829433.001]
  • [Cites] Anticancer Drugs. 2002 Apr;13(4):353-7 [11984080.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:217-20 [15251963.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:221-7 [15251964.001]
  • [Cites] Anal Biochem. 1980 Mar 1;102(2):344-52 [6158890.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2182-90 [3001145.001]
  • [Cites] Mol Biol (Mosk). 1988 Nov-Dec;22(6):1667-72 [3252155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2315-24 [10325420.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1159-64 [10506932.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):873-7 [15560075.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):389-94 [10956415.001]
  • (PMID = 16641902.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2361269
  •  go-up   go-down


50. Li YJ, Wen G, Wang Q: [Expression of vascular endothelial growth factor and its receptor Flk-1/KDR in benign and malignant breast neoplasms]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jan;29(1):70-1, 74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of vascular endothelial growth factor and its receptor Flk-1/KDR in benign and malignant breast neoplasms].
  • OBJECTIVE: To investigate the differences in the expression of angiogenesis-related molecules between benign and malignant breast neoplasms.
  • METHODS: Thirty breast cancer patients (33 foci) and 30 with benign breast neoplasms (34 foci) were examined for CD34, vascular endothelial growth factor (VEGF) and Flk-1/KDR expressions using immunohistochemistry.
  • RESULTS: In patients with breast cancer, the microvessels densely distributed around the cancer nest.
  • The microvessel density (MVD) in the cancer patients was significantly higher than that in patients with benign tumors (34.48+/-8.34 vs 18.65+/-4.69, P<0.05).
  • In the breast cancer patients, strong VEGF expression was found in the epithelial cells and vascular endothelial cells around the breast carcinoma, and Flk-1/KDR was also strongly expressed in the vascular endothelial cells.
  • The expressions of VEGF and Flk-1/KDR were hardly detectable in the benign tumors.
  • CONCLUSION: VEGF is an important regulatory factor in promoting breast tumor angiogenesis.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218116.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


51. Galiè M, Farace P, Merigo F, Fiorini S, Tambalo S, Nicolato E, Sbarbati A, Marzola P: Washout of small molecular contrast agent in carcinoma-derived experimental tumors. Microvasc Res; 2009 Dec;78(3):370-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Washout of small molecular contrast agent in carcinoma-derived experimental tumors.
  • The use of contrast-enhanced magnetic resonance imaging (MRI) for the assessment of breast carcinomas reveals satisfactory sensitivity, but due to low specificity, it does not obviate the need for subsequent tissue sampling.
  • Its capability to differentiate benign from malignant lesion is under continuous investigation.
  • In particular, the study of the washout pattern is considered a promising tool to improve in vivo diagnosis and even to evaluate the response under chemotherapy.
  • To provide a comprehensive characterization of this parameter in malignant tumor models, in vivo mapping of the washout of small molecular contrast agent (Gd-DTPA, molecular weight 0.57 kDa) was carried out in three transplanted/spontaneous mammary tumors, which differed in their histopathological and microvascular features.
  • It resulted that in all models around 40% of tumor volume lacks efficient washout; washout areas are frequently, but not always, restricted to the tumor periphery and that non-washout areas are not restricted to necrotic regions.
  • Difference in the distribution of lymphatic vessels characterized spontaneous vs. transplanted tumors but did not produce a corresponding different washout pattern, confirming that Gd-DTPA drainage does not mainly depend on lymphatic architecture.
  • Finally, the efficiency of washout is correlated with parameters obtainable during the earlier phases of the enhancement curve and in malignant tumors it could be indirectly estimated from them.
  • [MeSH-major] Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Mammary Neoplasms, Experimental / diagnosis
  • [MeSH-minor] Animals. Female. Lymphatic Vessels / pathology. Mice. Mice, Inbred Strains. Microvessels / pathology. Neoplasm Transplantation. Neovascularization, Pathologic / pathology

  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804787.001).
  • [ISSN] 1095-9319
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


52. Glazebrook KN, Morton MJ, Reynolds C: Carcinoma of the breast mimicking an areolar dermal lesion. J Ultrasound Med; 2007 Aug;26(8):1083-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the breast mimicking an areolar dermal lesion.
  • OBJECTIVE: This report describes the sonographic features of 2 patients with invasive carcinoma of the breast that sonographically mimicked benign epithelial cysts of the areola.
  • Neither sonogram showed a deeper component arising from the underlying breast tissue that would suggest a breast origin.
  • CONCLUSIONS: Lesions in the subcutaneous tissue superficial to the anterior pectoral fascia are extraparenchymal in origin and typically are benign.
  • All types of breast abnormalities, including malignancies, may affect deeper lactiferous glands and ducts and extend into the areola, independent of nipple involvement.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Sebaceous Glands / pathology. Ultrasonography, Mammary
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness. Skin Diseases / pathology. Skin Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646371.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Li G, Passebosc-Faure K, Feng G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: MN/CA9: a potential gene marker for detection of malignant cells in effusions. Biomarkers; 2007 Mar-Apr;12(2):214-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of malignant cells in effusions has implications in diagnosis, tumour staging and prognosis.
  • MN/CA9 has proved to be a valuable marker in many cancers such as lung, breast, colon, kidney, etc.
  • Seventy-one pleural effusions including 59 malignant effusions from patients with cancer, and 12 patients with benign diseases as a control, were subjected to RT-PCR for detection of MN/CA9 gene expression.
  • MN/CA9 gene expression was detected in 53/59 (89.8%) pleural effusions from cancer patients (15/16 for breast cancers, 10/11 for lung cancers, 4/4 for ovary cancers, 2/3 for colon-rectal cancers, 5/6 for cancers of unknown site, 7/8 for mesothelioma and 10/11 for other cancers).
  • [MeSH-major] Antigens, Neoplasm / analysis. Carbonic Anhydrases / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Case-Control Studies. Gene Expression. Humans. Neoplasm Proteins / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536770.001).
  • [ISSN] 1354-750X
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


54. Harsløf SS, Andersen LM, Hoyer U, Christiansen JJ: [Breast cancer metastasis to the colon]. Ugeskr Laeger; 2010 Aug 23;172(34):2309-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast cancer metastasis to the colon].
  • She was diagnosed with metastases of a carcinoma to the colon; the immunohistochemical profile made lobular breast cancer the most likely primary tumour.
  • But despite thorough examination, such tumour was never found.
  • Twenty-two years earlier, the patient underwent surgery for a benign breast tumour.
  • The benign diagnosis was confirmed in new slides from the then removed tissue.
  • Metastases from breast cancer to the colon are rare, and a primary tumour is usually found.
  • In this case report, however, no primary tumour was found.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonic Neoplasms / secondary. Female. Humans. Neoplasms, Unknown Primary / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20727298.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


55. Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L: Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat; 2010 Dec;124(3):677-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
  • HAb18G is a recently identified hepatoma-associated antigen and its association with tumor growth, invasion, and angiogenesis has been studied in a variety of tumors.
  • However, its role in the tumor progression of breast cancer has not been explored.
  • HAb18G expression was examined by immunohistochemistry in pathological sections of 1,637 breast tissue samples and by in situ hybridization in 41 cases of invasive breast carcinomas (BC).
  • While not detected in any cases of tumor-like conditions or benign tumors of breast, and only rarely in normal tissue (4.4%), HAb18G expression was gradually up-regulated from atypical ductal hyperplasia (27.3%), to ductal carcinoma-in situ (59.8%), and to BC (61.4%) (P < 0.01).
  • In an expanded group of 186 BC patients with proper follow up, our previous findings were confirmed: HAb18G expression was significantly associated with local recurrence, distant metastasis and tumor mortality (P < 0.01).
  • We also demonstrated that up-regulated tumor expression of HAb18G was a significant predictor of reduced disease progression-free survival rate and a shorter overall survival, independent of systemic therapies.
  • Further evaluation of this new marker in breast cancer is indicated.
  • [MeSH-major] Antigens, CD147 / analysis. Biomarkers, Tumor / analysis. Breast Neoplasms / immunology. Carcinoma / immunology. Carcinoma, Intraductal, Noninfiltrating / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. China. Disease-Free Survival. Female. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. Time Factors. Treatment Outcome. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213083.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 136894-56-9 / Antigens, CD147; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


56. Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6862-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
  • EXPERIMENTAL DESIGN: One hundred fourteen serous effusions from 71 patients with tumors and 43 patients with benign diseases were subjected to RT-PCR for expression of carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (Ep-CAM), E-cadherin, mammaglobin, mucin 1 (MUC1) isoforms MUC1/REP, MUC1/Y, and MUC1/Z, calretinin, and Wilms' tumor 1 susceptibility gene.
  • Moreover, CEA and mammaglobin were specifically expressed in epithelial malignancies, and mammaglobin was mainly expressed in effusions from breast carcinoma (97.3% of specificity).
  • CONCLUSIONS: A combination of cytology and RT-PCR analysis of CEA and Ep-CAM significantly improved the detection sensitivity of tumor cells in serous effusions.
  • RT-PCR analysis of CEA, Ep-CAM, and mammaglobin in serous effusions could be a beneficial adjunct to cytology for the diagnosis of malignancy.
  • [MeSH-major] Biomarkers, Tumor. Genetic Predisposition to Disease. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Aged. Antigens / biosynthesis. Antigens, Neoplasm / biosynthesis. Ascites / metabolism. Cadherins / biosynthesis. Calbindin 2. Carcinoembryonic Antigen / biosynthesis. Carcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Cell Line, Tumor. DNA Primers / chemistry. Female. Genes, Wilms Tumor. Glycoproteins / biosynthesis. Humans. Male. Mammaglobin A. Middle Aged. Mucin-1. Mucins / biosynthesis. Neoplasm Proteins / biosynthesis. Oligonucleotides, Antisense / chemistry. Pleural Effusion. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. S100 Calcium Binding Protein G / biosynthesis. Sensitivity and Specificity. Uteroglobin / biosynthesis. WT1 Proteins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Cadherins; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / EPCAM protein, human; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Mucins; 0 / Neoplasm Proteins; 0 / Oligonucleotides, Antisense; 0 / S100 Calcium Binding Protein G; 0 / SCGB2A2 protein, human; 0 / WT1 Proteins; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


57. Iyengar P, Ali SZ, Brogi E: Fine-needle aspiration cytology of mammary adenomyoepithelioma: a study of 12 patients. Cancer; 2006 Aug 25;108(4):250-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adenomyoepithelioma (AME) of the breast is a rare neoplasm that is characterized by a biphasic proliferation of epithelial and myoepithelial cells.
  • METHODS: The authors conducted a retrospective evaluation of cytologic findings in fine-needle aspiration biopsy (FNAB) material from 12 patients with histologically proven benign AMEs of the breast.
  • None of the patients were diagnosed originally with AME: Two tumors were classified as benign and consistent with fibroadenoma, 6 tumors were atypical, 2 tumors were suspicious for carcinoma, and 2 tumors were positive for malignant cells.
  • CONCLUSIONS: Because of the varied histology of AME, cytologic diagnosis of this neoplasm can be very challenging.
  • Conservative diagnosis and further histologic evaluation is recommended for these patients.
  • [MeSH-major] Adenoma / pathology. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Myoepithelioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials as Topic. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16544319.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Riddle ND, Yamauchi H, Caracciolo JT, Cheong D, Khakpour N, Bui MM: Giant cell tumor of the anterior rib masquerading as a breast mass: a case report and review of current literature. Cases J; 2010;3:51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the anterior rib masquerading as a breast mass: a case report and review of current literature.
  • INTRODUCTION: Giant cell tumor (GCT) is an aggressive, but usually benign bone neoplasm most commonly arising in the metaphysis/epiphyses of long bones.
  • While they are categorized as benign tumors, they can be locally aggressive and clinically have metastatic potential.
  • The most common locations of this tumor include the distal femur, proximal tibia, and distal radius.
  • We report a GCT arising in an atypical location and mimicking a breast mass.
  • Radiologically, the initial impression included a deep-seated breast cancer with local chest wall invasion.
  • CONCLUSION: The histological features of bland mononuclear and multinucleated giant cells along with the lack of any additional mesenchymal elements led to the diagnosis of giant cell tumor.
  • Resection of tumor was performed.
  • This case is important as it shows where the physician must keep this diagnosis in mind whenever a deeply located breast mast is present.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 1992;21(7):482-8 [1439904.001]
  • [Cites] Respir Med. 1991 Sep;85(5):435-6 [1759012.001]
  • [Cites] J Surg Oncol. 1989 Feb;40(2):128-31 [2492623.001]
  • [Cites] Intern Med. 2007;46(14):1151-2 [17634719.001]
  • [Cites] Skeletal Radiol. 2003 Feb;32(2):107-10 [12589492.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jun;20(4):351-5 [12746169.001]
  • [Cites] Arch Orthop Trauma Surg. 2000;120(3-4):231-2 [10738893.001]
  • (PMID = 20205847.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2825505
  •  go-up   go-down


59. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


60. Feng R, Liu X, Guo Z, Li J: Purification and characterization of 66-kDa glycoprotein from human breast carcinoma. Cancer Sci; 2007 Sep;98(9):1344-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purification and characterization of 66-kDa glycoprotein from human breast carcinoma.
  • We extracted a 66-kDa glycoprotein (GP-1D8) from breast invasive ductal carcinoma tissues.
  • Immunocytochemical and immunohistochemical analysis revealed strong expression of GP-1D8 protein in the cytoplasm of MCF-7 cells and different types of breast carcinoma tissues, but GP-1D8 is absent in normal breast and benign breast tumor tissues.
  • This is the first time human breast carcinoma tissues and MCF-7 cells have been shown to express a 66-kDa glycoprotein similar to human albumin precursor.
  • [MeSH-major] Biomarkers, Tumor / isolation & purification. Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Glycoproteins / isolation & purification. Neoplasm Proteins / isolation & purification
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Female. Humans. Mice. Mice, Inbred BALB C. Molecular Sequence Data. Peptide Fragments / chemistry. Protein Precursors / chemistry. Serum Albumin / chemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640306.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / Serum Albumin
  •  go-up   go-down


61. Buch A, Rout P, Makhija P: Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump. Indian J Pathol Microbiol; 2006 Apr;49(2):259-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyoepithelioma with phyllodes tumor--a rare combination in a solitary breast lump.
  • An unusual combination of two benign breast neoplasms adenomyoepithelioma and phyllodes tumor presenting as a solitary breast lump have been described.
  • Both these tumors have tendencies to recur and have malignant potential.
  • This patient also presented with a recurrent breast neoplasm.
  • [MeSH-major] Adenomyoma / pathology. Breast Neoplasms / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Indian J Pathol Microbiol. 2006 Jul;49(3):476
  • (PMID = 16933731.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


62. Oldenburg A, Albrecht T: [Baseline and contrast-enhanced ultrasound of the liver in tumor patients]. Ultraschall Med; 2008 Oct;29(5):488-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Baseline and contrast-enhanced ultrasound of the liver in tumor patients].
  • Conventional sonography is the most commonly used modality for liver imaging in tumor patients.
  • The majority of liver metastases are hypoechoic and well defined in baseline ultrasound (US), while detection of isoechoic or small liver metastases <1 cm is difficult and the differentiation of liver metastases from benign liver lesions and other malignant liver tumors can be impossible with baseline US.
  • Furthermore, the typical enhancement patterns of the different benign and malignant liver lesions allow reliable characterization and differentiation from liver metastases in the majority of cases.
  • This paper provides information about the advantages and expedient application of contrast-enhanced ultrasound (CEUS) in tumor patients.
  • [MeSH-major] Contrast Media. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Neoplasm Metastasis / ultrasonography
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Colonic Neoplasms / pathology. Colonic Neoplasms / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neovascularization, Pathologic / ultrasonography. Reproducibility of Results. Sarcoma, Ewing / pathology. Sarcoma, Ewing / ultrasonography. Ultrasonography, Doppler / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ultraschall Med. 2009 Apr;30(2):125-7 [19340726.001]
  • (PMID = 19241505.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


63. Stolnicu S, Rădulescu D, Pleşea IE, Dobru D, Podoleanu C, Pintilei DR: The value of intraoperative diagnosis in breast lesions. Rom J Morphol Embryol; 2006;47(2):119-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of intraoperative diagnosis in breast lesions.
  • Frozen section examination is aimed at making a preoperative diagnosis, determining the benign or malignant nature of a breast lesion, but also the most suitable surgical procedure.
  • The sensitivity and specificity of this method and the causes of discrepancies were analyzed in a retrospective study of 2 177 breast lesions.
  • METHOD: 1,150 frozen sections from 2,177 breast lesions were performed in the interval 1999-2005.
  • The following terms were used for describing the intraoperative diagnosis: negative, positive, and await paraffin section.
  • After the frozen section diagnosis was made, the frozen tissue was thawed to room temperature and fixed in formalin overnight for further paraffin processing.
  • In 7% of the cases the diagnosis could not be made on frozen section.
  • CONCLUSIONS: Despite the raging popularity of aspiration cytology, frozen section still stands out as the method of choice for rapid diagnosis.
  • [MeSH-major] Breast Diseases / surgery. Breast Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / pathology. Fibrocystic Breast Disease / pathology. Humans. Intraoperative Period. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106518.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


64. Yang GZ, Li J, Ding HY: [Nipple adenoma: report of 18 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):614-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinicopathological and immunohistochemical features, diagnosis and differential diagnosis of nipple adenoma of the breast.
  • RESULTS: The neoplasms were localized at nipples or under the areola of breast, adherent to the epidermis, mainly composed of dilated ducts in a tubular appearance associated with fibrotic matrix.
  • The tumor cells were crowding, lack of an uniform morphology and polarity with intact myoepithelial cells around the ducts.
  • CONCLUSIONS: Nipple adenoma is an infrequent type of benign breast neoplasm, presenting as sclerosing papilloma, papillomatosis or florid sclerosing adenosis.
  • A correct diagnosis is based on the peculiar location and morphology of the tumor, and immunohistochemistry is helpful in some cases.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Nipples / pathology
  • [MeSH-minor] Adult. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Keratin-5 / metabolism. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CK-34 beta E12; 0 / Keratin-5; 68238-35-7 / Keratins
  •  go-up   go-down


65. Ellis IO, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, Al-Sam S, Anderson N, Bobrow L, Buley I, Connolly CE, Dallimore NS, Hales S, Hanby A, Humphreys S, Knox F, Lowe J, Macartney J, Nash R, Parham D, Patnick J, Pinder SE, Quinn CM, Robertson AJ, Shrimankar J, Walker RA, Winder R: Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol; 2006 Feb;59(2):138-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of a national external quality assessment scheme for breast pathology in the UK.
  • BACKGROUND: This article presents the results and observed effects of the UK National Health Service Breast Screening Programme (NHSBSP) external quality assurance scheme in breast histopathology.
  • (1) where consistency is naturally very high-this included diagnosing in situ and invasive carcinomas (and certain distinctive subtypes) and uncomplicated benign lesions;.
  • Even in cases where there is a high level of agreement on tumour size, a few widely outlying measurements were encountered, for which no explanation is readily forthcoming.
  • CONCLUSIONS: These results broadly confirm the robustness of the systems of breast disease diagnosis and classification adopted by the NHSBSP, and also identify areas where improvement or new approaches are required.
  • [MeSH-major] Breast Neoplasms / pathology. Quality Assurance, Health Care
  • [MeSH-minor] Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Clinical Competence. Female. Great Britain. Humans. Mass Screening / standards. Neoplasm Invasiveness. Prognosis. State Medicine / standards

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1769-72 [10974624.001]
  • [Cites] Virchows Arch. 1999 Jan;434(1):3-10 [10071228.001]
  • [Cites] CA Cancer J Clin. 2002 Sep-Oct;52(5):277-300 [12363326.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1049-57 [6318957.001]
  • [Cites] Breast Cancer Res Treat. 1989 Oct;14(1):91-9 [2605345.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):209-21 [1847606.001]
  • [Cites] BMJ. 1992 Jun 6;304(6840):1491-4 [1611375.001]
  • [Cites] Hum Pathol. 1992 Oct;23(10):1095-7 [1328030.001]
  • [Cites] Am J Surg Pathol. 1992 Dec;16(12):1133-43 [1463092.001]
  • [Cites] Arch Pathol Lab Med. 1993 Oct;117(10):1005-8 [8215820.001]
  • [Cites] Histopathology. 1994 Jan;24(1):41-7 [8144141.001]
  • [Cites] Eur J Cancer. 1994;30A(10):1414-9 [7833094.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):915-23 [9744307.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):365-71 [11979379.001]
  • (PMID = 16443727.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860326
  •  go-up   go-down


66. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol; 2005 Apr;192(4):1214-21; discussion 1221-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased risk includes women with at least 1 affected first-degree relative with ovarian cancer; a personal history of breast, ovarian, or colon cancer; > or =1 affected first- and second-degree relatives with breast and or ovarian cancer; inheritance of a breast cancer mutation from an affected family member, or membership within a recognized cancer syndrome.
  • A total of 98 women with persistent adnexal masses were identified, and 49 invasive surgical procedures were performed that diagnosed 37 benign ovarian tumors and 12 gynecologic malignancies.
  • All cancers were detected in asymptomatic women who had normal ultrasound and physical examinations 12 and 6 months before the cancer diagnosis.
  • Additionally 37 primary and 12 recurrent breast carcinomas were detected by physical examination.
  • A total of 184 women with genetic predisposition (breast cancer positive) have undergone a prophylactic bilateral salpingo-oophorectomy; 23% of these procedures found atypical hyperplasia, and unexpectedly, 2 women (1%) were found to have stage III (A and B) primary peritoneal carcinoma.
  • [MeSH-major] Mass Screening / methods. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / ultrasonography. Ovarian Neoplasms / pathology. Ovarian Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Age Distribution. Aged. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846205.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


67. Sheen-Chen SM, Liu YW, Eng HL, Chou FF: Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):715-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of hepatocyte growth factor in patients with breast cancer.
  • Elevated hepatocyte growth factor content in tumor tissue was reported to predict a more aggressive biology in non-small cell lung cancer patients.
  • However, there is still limited knowledge about the role of HGF in breast cancer.
  • This study was designed with the aim to elucidate the possible relationship between the preoperative circulating soluble HGF and breast cancer.
  • MATERIALS AND METHODS: One hundred twenty-four consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated.
  • The control group consisted of 35 patients with benign breast tumor (20 with fibrocystic disease and 15 with fibroadenoma).
  • The data on primary tumor staging, age, estrogen receptor status, lymph node status, distant metastases status, histologic grading, and tumor-node-metastasis (TNM) staging were reviewed and recorded.
  • RESULTS: The mean value of serum soluble HGF in patients with invasive breast cancer was 529.05 +/- 123.33 pg/mL and that of control group was 343.00+/- 31.03 pg/mL and the difference was significant (P < 0.001).
  • Furthermore, there were significantly higher serum levels of soluble HGF in patients with negative estrogen receptor (P = 0.035), in patients with poorer differentiated tumor (P < 0.001), in patients with more advanced primary tumor staging (P < 0.001), in patients with more advanced lymph node status (P < 0.001), in patients with distant metastases (P < 0.001), and in patients with more advanced TNM staging (P < 0.001).
  • Thus, preoperative serum soluble HGF levels might reflect the severity of invasive breast cancer and deserve further evaluation.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / pathology. Hepatocyte Growth Factor / blood. Neoplasm Invasiveness
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767355.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


68. Dillon MF, Quinn CM, McDermott EW, O'Doherty A, O'Higgins N, Hill AD: Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery; 2006 Nov;140(5):779-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle core biopsy in the diagnosis of phyllodes neoplasm.
  • BACKGROUND: Accurate identification of phyllodes neoplasms without surgical intervention is difficult, reducing the ability to manage "benign" lumps non-operatively and impacting on the open benign biopsy rate.
  • Needle core biopsy is considered to be a highly accurate technique in the diagnosis of breast carcinoma.
  • Its accuracy in the diagnosis of phyllodes neoplasm has not been established.
  • RESULTS: Twenty-three patients had phyllodes neoplasm on excisional biopsy with prior core biopsy findings as follows: phyllodes neoplasm (n=2), "equivocal" for phyllodes neoplasm (n=12), fibroadenoma (n=3), benign (n=6).
  • The false negative rate for phyllodes neoplasm was therefore 39% (n=9/23).
  • Of the total biopsy series, 35 patients had a core biopsy suggesting the possibility of phyllodes neoplasm.
  • Of these, 32% (n=11) were found to be phyllodes neoplasm on excision, 3% (n=1) phyllodes neoplasm with breast carcinoma, 6% (n=2) breast carcinoma, and 3% (n=1) sarcoma.
  • When a preference for phyllodes neoplasm (n=4) was stated on the equivocal core biopsies, excision correlated with the stated preference; this correlation also occurred in 90% (n=9/10) of core biopsies where fibroadenoma was favored.
  • CONCLUSIONS: Needle core biopsy rarely produces a definite preoperative diagnosis of phyllodes neoplasm.
  • A diagnosis of fibroadenoma or equivocal phyllodes neoplasm on core biopsy should not prevent excision if clinical suspicion remains.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Diagnostic Errors. Phyllodes Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084721.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Gozzi G, Martinoli C, Conti GM, Ganzetti A, Bodini M, Fiorentino C, Marini UP, Santini D, Bacigalupo L: Screening mammography interpretation test: more frequent mistakes. Radiol Med; 2005 Mar;109(3):268-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mammograms had been taken in the four standard projections and placed on four multi-panel diaphanoscopes, each displaying a set of 40 cases comprising benign and malignant cases in equal proportions.
  • As regards the 23 most frequently misread cases, these were 10/32 (31.25%) mammograms positive for malignancy and 13/128 (10.15%) negative mammograms or mammograms showing benign disease.
  • The 13 cases of benign disease--as established by histology or long-term follow-up--mistaken for malignancies by the test participants were fibrocystic breast disease in 5 cases, surgical scar in 1 case, ABBI scar in 1 case, radial scar in 2 cases, microcalcifications that had remained stable for years in 2 cases, focal sclero-adenosis in 1 case and sclero-elastosis in 1 case.
  • CONCLUSIONS: The errors were due to microcalcifications, benign disease simulating a neoplasm, overlapping tissue, visibility of a lesion in one projection only, lesion site in relation to the corpus mammae, missed areas of asymmetry.
  • Attention must be paid to these signs of focal breast disease since, if correctly evaluated, they enable the early diagnosis of low-grade carcinomas that frequently carry a favourable prognosis.
  • [MeSH-major] Breast Neoplasms / radiography. Diagnostic Errors. Mammography. Mass Screening. Radiology / standards
  • [MeSH-minor] Adenocarcinoma / radiography. Breast Diseases / surgery. Calcinosis / radiography. Carcinoma in Situ / radiography. Carcinoma, Ductal, Breast / radiography. Cicatrix / surgery. False Negative Reactions. False Positive Reactions. Female. Fibrocystic Breast Disease / radiography. Follow-Up Studies. Humans. Observer Variation


70. Oba M, Sasaki M, Ii T, Hoso M, Ajisaka H, Matsuki N, Miwa K: A case of lymphocytic mastopathy requiring differential diagnosis from primary breast lymphoma. Breast Cancer; 2009;16(2):141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of lymphocytic mastopathy requiring differential diagnosis from primary breast lymphoma.
  • Lymphocytic mastopathy is a benign breast disease characterized by dense fibrosis, lobular atrophy, and aggregates of lymphocytes in a periductal and perivascular distribution.
  • Here, we report a case of the disease clinically and radiologically mimicking primary breast neoplasms.
  • The patient was a 50-year-old woman without diabetes who presented with two firm lumps in her right breast.
  • Breast imaging findings from mammography, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI), respectively, revealed an abnormal appearance suspicious of malignancy.
  • A core-needle biopsy specimen showed atypical accumulation of lymphoid cells, which was not easy to differentiate from primary breast lymphomas.
  • In our case, it was difficult to distinguish this entity from breast cancer or low-grade B-cell lymphoma without surgical biopsy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphocytes / pathology. Lymphoma / diagnosis. Mastitis / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Radiopharmaceuticals. Tomography, X-Ray Computed. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769994.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Roumen RM, Kuijt GP, Liem LH: [The sentinel lymph node procedure also feasible in patients with recurrent breast cancer]. Ned Tijdschr Geneeskd; 2008 Jan 5;152(1):13-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The sentinel lymph node procedure also feasible in patients with recurrent breast cancer].
  • [Transliterated title] Schildwachtklierprocedure: ook een mogelijkheid bij patiënten met een recidief van een mammacarcinoom.
  • The sentinel lymph node (SLN) concept has become a standard option for the diagnosis and treatment of patients with primary invasive breast cancer.
  • The implementation of this SLN concept has created a new category of patients: those who had breast-conserving therapy without complete axillary lymph node dissection following a negative SLN biopsy.
  • In cases of local relapse in the ipsilateral breast, questions arise on the lymphatic drainage of this new tumour.
  • Such is also the case for patients who have been treated for ductal carcinoma in situ, who have had a previous mastectomy, or even after previous benign breast or axillary surgery.
  • To date the literature on SLN biopsy in patients with recurrent breast cancer is scarce: only to publications dealing with 116 patients.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Lymphatic Metastasis. Neoplasm Recurrence, Local / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Axilla. Female. Humans. Lymph Node Excision. Mastectomy, Segmental. Neoplasm Staging. Reoperation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2008 Jan 5;152(1):10-2 [18240753.001]
  • (PMID = 18240754.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 21
  •  go-up   go-down


72. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • A two-way ANOVA model identified probe sets with differential expression in malignant and benign lesions while adjusting for scan dates.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • In the validation set (n=71), the molecular predictor accurately classified 68 of 71 tumours (96%, 88-99%).
  • When the 165 samples were taken into account, 37 858 exon probe sets (5.4%) and 3733 genes (7.0%) were differently expressed in malignant and benign lesions (threshold: adjusted p<0.05).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


73. Malhaire C, El Khoury C, Thibault F, Athanasiou A, Petrow P, Ollivier L, Tardivon A: Vacuum-assisted biopsies under MR guidance: results of 72 procedures. Eur Radiol; 2010 Jul;20(7):1554-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical accuracy of magnetic resonance imaging-guided breast vacuum-assisted biopsy (MR-VAB).
  • RESULTS: Twenty-three patients (median age 51 years) were at high risk (BRCA1 = 11, BRCA2 = 7, familial risk = 5), 23 had a suspected local recurrence of breast cancer.
  • According to histopathology results, 29 lesions were benign, 10 were high-risk (papillary = 2, radial scar = 1, atypical epithelial hyperplasia = 7) and 33 malignant (ductal carcinoma in situ = 8, invasive cancers = 25).
  • CONCLUSION: MRI-guided VAB represents an accurate tool for the histological diagnosis of lesions visible only at MRI.
  • [MeSH-major] Biopsy. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bleomycin. Breast / surgery. Dactinomycin. Female. Humans. Middle Aged. Neoplasm Staging. Radiography. Retrospective Studies. Tumor Burden. Vacuum. Vinblastine

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2004 Feb;198(2):240-1 [14759781.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):347-51 [12540431.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1725-31 [15248080.001]
  • [Cites] AJR Am J Roentgenol. 2008 Dec;191(6):1798-804 [19020252.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):721-7 [11222213.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):468-74 [17646475.001]
  • [Cites] Acta Radiol. 2006 Nov;47(9):907-13 [17077039.001]
  • [Cites] AJR Am J Roentgenol. 2009 Apr;192(4):1128-34 [19304724.001]
  • [Cites] AJR Am J Roentgenol. 2003 Nov;181(5):1283-93 [14573421.001]
  • [Cites] Radiology. 2006 Jan;238(1):54-61 [16304093.001]
  • [Cites] N Engl J Med. 2004 Jul 29;351(5):427-37 [15282350.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):171-8 [12076929.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1782-7 [15908530.001]
  • [Cites] AJR Am J Roentgenol. 2009 Feb;192(2):341-51 [19155393.001]
  • [Cites] Eur J Radiol. 2009 Nov;72(2):289-94 [18723305.001]
  • [Cites] Am J Hum Genet. 1991 Feb;48(2):232-42 [1990835.001]
  • [Cites] Lancet. 2005 May 21-27;365(9473):1769-78 [15910949.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3248-58 [18474876.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):386-91 [18202414.001]
  • [Cites] AJR Am J Roentgenol. 2007 Oct;189(4):852-9 [17885056.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):352-3 [18202408.001]
  • [Cites] Radiology. 2007 Aug;244(2):356-78 [17641361.001]
  • [Cites] Radiology. 2007 Sep;244(3):672-91 [17709824.001]
  • [Cites] Eur Radiol. 2002 Jun;12(6):1463-70 [12042955.001]
  • [Cites] Radiology. 1999 Aug;212(2):543-9 [10429716.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):982-90 [16456807.001]
  • [Cites] Eur Radiol. 1999;9(8):1656-65 [10525886.001]
  • [Cites] Radiology. 2007 Aug;244(2):381-8 [17641362.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jun;186(6):1733-6 [16714667.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1323-9 [10541112.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):183-93 [15972421.001]
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Eur Radiol. 2008 Jan;18(1):168-76 [17609959.001]
  • (PMID = 20119729.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 1CC1JFE158 / Dactinomycin; 5V9KLZ54CY / Vinblastine; VAB protocol
  •  go-up   go-down


74. Abbasi M, Tarafdari A, Esteghamati A, Vejdani K, Nakhjavani M: Insulin resistance and breast carcinogenesis: a cross-sectional study among Iranian women with breast mass. Metab Syndr Relat Disord; 2010 Oct;8(5):411-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin resistance and breast carcinogenesis: a cross-sectional study among Iranian women with breast mass.
  • Despite existing epidemiologic data concerning the increased incidence of breast cancer in diabetes type 2, the association between insulin resistance and breast carcinogenesis is not yet well defined.
  • In this cross-sectional study, we examined the homeostatic model assessment values of insulin resistance (HOMA-IR) among 82 patients with malignant breast tumor, 48 subjects with benign breast mass, and 838 healthy Iranian women.
  • Age and central obesity-adjusted HOMA-IR values were 3.6 [95% confidence interval (CI), 2.8-4.4], 2.3 (1.7-2.9), and 1.7(1.6-1.8) correspondingly in subjects with malignant breast tumor, those with benign breast mass, and healthy subjects.
  • The interaction effect of age on the association between breast mass (malignant/ benign /no breast mass) with HOMA-IR values was significant [F(54) = 10, P < 0.001, partial eta squared = 0.03].
  • We conclude that the noted linkage between insulin resistance and breast cancer may indicate an underlying pathology of mammary carcinogenesis.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / pathology. Insulin Resistance

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20874423.001).
  • [ISSN] 1557-8518
  • [Journal-full-title] Metabolic syndrome and related disorders
  • [ISO-abbreviation] Metab Syndr Relat Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / C-Peptide; 0 / Insulin
  •  go-up   go-down


75. Baez E, Strathmann K, Vetter M, Madjar H, Hackelöer BJ: Likelihood of malignancy in breast lesions characterised by ultrasound with a combined diagnostic score. Ultrasound Med Biol; 2005 Feb;31(2):179-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Likelihood of malignancy in breast lesions characterised by ultrasound with a combined diagnostic score.
  • To determine the positive predictive value of breast ultrasound (US) categories and US features, isolated and in combination, 398 consecutive sonographically diagnosed breast tumours with histologic or cytologic diagnosis were reviewed.
  • Tumour characterisation and the sonographer's diagnoses were recorded prospectively using the diagnostic classification of the European Society of Mastology (EUSOMA) (U2 = probably benign lesion, U3 = an abnormality present of indeterminate significance, U4 = features suspicious of malignancy).
  • US-guided biopsy revealed 338 benign and 60 (55 invasive and 5 noninvasive) malignant lesions.
  • If all breast tumours classified U3 and U4 were to be tested, every second biopsy (48.3%) would have revealed a carcinoma with a negative predictive value of 99.3%.
  • The frequency of carcinoma in sonographically benign lesions (U2 or score 1) was 0.7 and 2.2%, respectively, an incidence similar to that with mammographic lesions classified as BI-RADS 3 (Breast Imaging Reporting and Data System, probably benign, short interval follow-up suggested).
  • Thus, given that clinical symptoms and real-time imaging influence the sonographer's interpretation, the proposed diagnostic score can improve the diagnostic accuracy of the breast sonogram with the result of reducing invasive testing and maintaining a high detection rate.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle / methods. Carcinoma in Situ / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Lobular / ultrasonography. Female. Humans. Middle Aged. Neoplasm Invasiveness / ultrasonography. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708456.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Szubert Z, Sobala W: [Health reasons for work disability among municipal transport drivers]. Med Pr; 2005;56(4):285-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diseases of the musculoskeletal system were major causes of sickness absence among female tram drivers (24%), whereas malignant and benign neoplasms of breast and uterine myoma in 24% of female transport service workers.
  • CONCLUSIONS: The results of the analysis are in agreement with the literature findings and provide explicit evidence that employment in the municipal transport system is the risk factor responsible for the development of serious diseases such as musculoskeletal disorders and neoplasms.
  • [MeSH-major] Disabled Persons / statistics & numerical data. Occupational Diseases / diagnosis. Occupational Diseases / epidemiology. Transportation
  • [MeSH-minor] Aged. Cardiovascular Diseases / diagnosis. Cardiovascular Diseases / epidemiology. Disability Evaluation. Female. Health Status. Humans. Male. Middle Aged. Movement Disorders / diagnosis. Movement Disorders / epidemiology. Poland / epidemiology. Risk Factors. Severity of Illness Index. Urban Population / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Disabilities.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457365.001).
  • [ISSN] 0465-5893
  • [Journal-full-title] Medycyna pracy
  • [ISO-abbreviation] Med Pr
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


77. Ying MG, Chen Q, Ye YB, Chen HJ, Chen X, Zheng HY, Wu F: [Application of serum proteomic mass spectrum analysis in breast cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):698-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of serum proteomic mass spectrum analysis in breast cancer].
  • OBJECTIVE: To analyze the characteristics of serum proteins mass spectra in healthy controls, benign breast tumors, and CA15-3 negative or CA15-3 positive breast cancer patients by surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS).
  • METHODS: Tissue samples of 113 cases of breast cancer (93 case of CA15-3 negative, 20 case of CA15-3 positive), 103 cases of benign breast tumor and 92 cases of healthy controls were examined and analyzed by SELDI and protein chip (CM10) techniques.
  • RESULTS: Twelve significantly different protein peaks were found in serum samples between breast cancer patients and healthy controls.
  • Eleven significantly different peaks were found between benign breast tumor patients and healthy controls.
  • By combined analysis of those three different protein mass spectra, the peak 15 952 was found to be significantly different between breast cancer group and healthy controls, and the peak 7985 was significantly different among breast cancer group, benign breast tumor group and health controls.
  • The blind test with the differential proteins for the serum samples of 93 cases of CA15-3 negative breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 80.6% and specificity was 91.7%.
  • The blind test in 20 cases of CA15-3 positive breast cancer and 36 cases of benign breast tumors showed that the sensitivity was 75.0% and specificity was 91.7%.
  • Four significantly different protein peaks were found between the benign breast tumor patients and CA15-3 negative breast cancer patients.
  • CONCLUSION: Significantly different protein peaks can be screened out in breast cancer, benign breast tumor patients and healthy controls by SELDI-TOF-MS analysis.
  • [MeSH-major] Blood Proteins / metabolism. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis. Proteomics / methods
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Adenoma / metabolism. Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Female. Humans. Middle Aged. Mucin-1 / metabolism. Protein Array Analysis. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122387.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Mucin-1
  •  go-up   go-down


78. Zheng YF, Kong HW, Xiong JH, Lv S, Xu GW: Clinical significance and prognostic value of urinary nucleosides in breast cancer patients. Clin Biochem; 2005 Jan;38(1):24-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance and prognostic value of urinary nucleosides in breast cancer patients.
  • OBJECTIVE: Thirteen urinary nucleosides, primarily degradation products of tRNA, were evaluated as potential tumor markers for breast cancer patients.
  • DESIGN AND METHODS: The micellar electrokinetic chromatography (MEKC) method has been used to analyze the urinary nucleosides in 41 healthy controls, 20 patients with benign breast tumors, and 26 breast cancer patients.
  • RESULTS: Urinary nucleoside concentrations of breast cancer patients were found to increase significantly compared to those of patients with benign breast tumors and healthy controls.
  • By using 13 nucleoside concentrations as data vectors for principal component analysis (PCA), 73% (19/26) of breast cancer patients were correctly identified from healthy controls, while only 20% (4/20) of patients with benign breast tumors were indistinguishable from breast cancer patients.
  • The mean level of all forms of urinary nucleosides in patients with metastatic breast cancer was higher than that in patients with primary breast cancer.
  • CONCLUSION: The results indicate that urinary nucleosides may be useful as tumor markers for breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Nucleosides

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15607313.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nucleosides
  •  go-up   go-down


79. Hao RT, Zhang XH, Pan YF, Liu HG, Xiang YQ, Wan L, Wu XL: Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer. J Cancer Res Clin Oncol; 2010 Sep;136(9):1349-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
  • PURPOSE: The aim of this study was to investigate the expression of the PRL-3 in human invasive breast cancer and to evaluate its clinical and prognostic significance.
  • Its potential role in the invasive-metastatic properties of invasive breast cancer was also investigated.
  • METHODS: Protein expression of PRL-3 was evaluated by immunohistochemistry for a consecutive series of 82 invasive human breast cancer tissues and 63 matched lymph node metastases, including PRL-3 mRNA expression analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) in malignant, nonmalignant breast tissue samples and lymph node metastases.
  • RESULTS: We found that 70.7% patients expressed a high level of PRL-3 protein in their tumors, and its over expression was positive correlated with lymph node metastasis (LNM) (P = 0.011).
  • Moreover, The PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue, while increased expression of PRL-3 mRNA was significantly associated with LNM (P = 0.002).
  • Increasing the risk of tumor metastasis (OR = 3.889).
  • Our results also imply that PRL-3 might be a novel molecular marker for predicting relapse of invasive breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / enzymology. Neoplasm Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Invasiveness / diagnosis. Prognosis. RNA, Messenger / biosynthesis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Mol Med. 2008 Aug;22(2):187-92 [18636172.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8 [11355880.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1517-22 [16873432.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2922-6 [17409395.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Mol Med. 2007 Mar-Apr;13(3-4):151-9 [17592549.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1307-12 [18684031.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):303-10 [17235563.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21444-52 [10747914.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37 [16875667.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2195-204 [15788667.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1179-84 [17440740.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Surg Today. 2007;37(8):646-51 [17643206.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7857-66 [15520192.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1439-47 [18561324.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):179-83 [16472776.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3153-61 [16540666.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] Science. 2001 Oct 12;294(5541):281-2 [11598274.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):219-29 [16505094.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11882-9 [14704153.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):347-54 [16832410.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9625-35 [17018620.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):945-51 [15326366.001]
  • [Cites] Mol Cell. 2008 May 9;30(3):303-14 [18471976.001]
  • (PMID = 20140626.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


80. Celis JE, Cabezón T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F: Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. Mol Oncol; 2009 Jun;3(3):220-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.
  • Invasive apocrine carcinomas (IACs), as defined by morphological features, correspond to 0.3-4% of all invasive ductal carcinomas (IDC), and despite the fact that they are histologically distinct from other breast lesions there are currently no standard molecular criteria available for their diagnosis and no unequivocal information as to their prognosis.
  • In an effort to address these concerns we have been using protein expression profiling technologies in combination with mass spectrometry and immunohistochemistry (IHC) to discover specific biomarkers that could allow us to molecularly characterize these lesions as well as to dissect some of the steps in the processes underlying breast apocrine metaplasia and development of precancerous apocrine lesions.
  • Establishing these apocrine-specific markers as best practice for the routine pathology evaluation of breast cancer, however, will require their validation in large cohorts of patients.
  • Towards this goal we have composed a panel of antibodies against components of an apocrine protein signature that includes probes against the apocrine-specific markers 15-prostaglandin dehydrogenase (15-PGDH), and acyl-CoA synthetase medium-chain family member 1 (ACSM1), in addition to a set of categorizing markers that are consistently expressed (AR, CD24) or not expressed (ERα, PgR, Bcl-2, and GATA-3) by apocrine metaplasia in benign breast lesions and apocrine sweat glands.
  • Samples were originally classified on the basis of cellular morphology with all cases having more than 90% of the tumour cells exhibiting cytological features typical of apocrine cells.
  • Our results demonstrate that IACs correspond to a distinct, even if heterogeneous, molecular subgroup of breast carcinomas that can be readily identified in an unbiased way using a combination of markers that recapitulate the phenotype of apocrine sweat glands (15-PGDH(+), ACSM1(+), AR(+), CD24(+), ERα(-), PgR(-), Bcl-2(-), and GATA-3(-)).
  • [MeSH-major] Apocrine Glands / metabolism. Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1313-20 [18042688.001]
  • [Cites] Acta Oncol. 2006;45(6):643-61 [16938807.001]
  • [Cites] Mod Pathol. 1994 Oct;7(8):813-8 [7838835.001]
  • [Cites] Biotechnol Annu Rev. 2008;14:143-70 [18606362.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] Pathol Biol (Paris). 2009 Jun;57(4):324-33 [19070972.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Breast. 2005 Feb;14(1):3-10 [15695074.001]
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2799-805 [19008097.001]
  • [Cites] Tissue Eng Part C Methods. 2008 Sep;14(3):261-71 [18694322.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1006-12 [17105822.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):149-59 [18212769.001]
  • [Cites] Curr Opin Biotechnol. 1999 Feb;10(1):16-21 [10047502.001]
  • [Cites] Mol Oncol. 2008 Dec;2(4):368-79 [19383358.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):235-44 [17329194.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1854-63 [16002278.001]
  • [Cites] Breast J. 2008 Mar-Apr;14(2):164-8 [18248561.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R53 [18559090.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Pathol Res Pract. 2005;201(7):479-86 [16164042.001]
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1795-809 [18632593.001]
  • [Cites] Histopathology. 2007 Mar;50(4):425-33 [17448017.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2463-71 [6254632.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2002 Dec;67(6):461-5 [12468268.001]
  • [Cites] Med Oncol. 1997 Jun;14(2):83-9 [9330267.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):339-46 [16892043.001]
  • [Cites] Br J Cancer. 2003 Jan 27;88(2):231-6 [12610508.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):830-5 [14871808.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Nat Methods. 2007 Apr;4(4):359-65 [17396127.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):462-83 [16316978.001]
  • [Cites] Histopathology. 2005 Aug;47(2):195-201 [16045781.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):24-32 [19383364.001]
  • [Cites] Pathol Res Pract. 1997;193(11-12):753-8 [9521507.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Cancer. 1968 Apr;21(4):756-63 [4296681.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2001;2:343-72 [11701654.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):832-5 [12766589.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Histopathology. 2008 Jan;52(1):108-18 [18171422.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Nov;4(11):1391-402 [18950281.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):532-41 [3717305.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Histopathology. 2008 Jan;52(1):3-10 [18171412.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):838-41 [10690175.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Pathobiology. 2008;75(2):119-31 [18544967.001]
  • [Cites] Mol Oncol. 2009 Jun;3(3):220-37 [19393583.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):201-9 [17187062.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):42-54 [19383286.001]
  • [Cites] J Gastrointest Cancer. 2007;38(2-4):78-82 [19031117.001]
  • [Cites] Breast J. 2003 Jul-Aug;9(4):335-6 [12846876.001]
  • [Cites] Pathology. 2009 Jan;41(1):68-76 [19089742.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Nature. 2005 Sep 22;437(7058):491-3 [16177777.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Feb;24(2):223-8 [3356211.001]
  • [Cites] Nat Clin Pract Urol. 2008 Jul;5(7):376-87 [18542103.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7917-25 [16140963.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):33-44 [19383365.001]
  • [Cites] Breast. 2005 Feb;14(1):1-2 [15695073.001]
  • [Cites] Breast Cancer Res. 2007;9(3):R30 [17504517.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Int J Clin Pract. 2008 Mar;62(3):444-9 [18194278.001]
  • [Cites] Mol Oncol. 2007 Sep;1(2):144-59 [18443658.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1041-55 [17129787.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):580-92 [17668425.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • (PMID = 19393583.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


81. Huang W, Li X, Morris EA, Tudorica LA, Seshan VE, Rooney WD, Tagge I, Wang Y, Xu J, Springer CS: The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc Natl Acad Sci U S A; 2008 Nov 18;105(46):17943-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo.
  • In analyses of routine DCE-MRI data from 22 patients with suspicious breast lesions initially ruled positive by institutional screening protocols, the SM K(trans) values for benign and malignant lesions exhibit considerable overlap.
  • A form of the shutter-speed model (SSM), which allows for finite exchange kinetics, agrees with the SM K(trans) value for each of the 15 benign lesions.
  • However, it reveals that the SM underestimates K(trans) for each of the seven malignant tumors in this population.
  • The fact that this phenomenon is unique to malignant tumors allows their complete discrimination from the benign lesions, as validated by comparison with gold-standard pathology analyses of subsequent biopsy tissue samples.
  • Likewise, the SM overestimates k(ep), particularly for the benign tumors.
  • Thus, incorporation of the SSM into the screening protocols would have precluded all 68% of the biopsy/pathology procedures that yielded benign findings.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Med. 2004 Nov;52(5):1110-7 [15508148.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):724-9 [15723402.001]
  • [Cites] NMR Biomed. 2005 May;18(3):173-85 [15578708.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5464-73 [16027440.001]
  • [Cites] Magn Reson Med. 2005 Dec;54(6):1351-9 [16247739.001]
  • [Cites] Breast. 2006 Feb;15(1):137-40 [16005227.001]
  • [Cites] Cancer. 2006 May 15;106(10):2104-12 [16604564.001]
  • [Cites] NMR Biomed. 2006 Oct;19(6):681-9 [16986117.001]
  • [Cites] Eur Radiol. 2006 Dec;16(12):2619-21 [17061066.001]
  • [Cites] Magn Reson Med. 2007 Jan;57(1):220-5 [17152087.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):467-72 [17337650.001]
  • [Cites] CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89 [17392385.001]
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1295-303 [17392300.001]
  • [Cites] Lancet. 2007 Aug 11;370(9586):485-92 [17693177.001]
  • [Cites] Cancer Invest. 2007 Oct;25(7):518-26 [18027149.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):166-75 [17768665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17937-42 [19008355.001]
  • [Cites] NMR Biomed. 2009 Feb;22(2):148-57 [18727151.001]
  • [Cites] N Engl J Med. 2007 Apr 5;356(14):1399-409 [17409321.001]
  • [Cites] Magn Reson Med. 2000 Oct;44(4):563-74 [11025512.001]
  • [Cites] Magn Reson Med. 2002 Jun;47(6):1110-20 [12111957.001]
  • [Cites] Magn Reson Med. 2003 Sep;50(3):493-9 [12939756.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1151-69 [14648563.001]
  • [Cites] Magn Reson Med. 2004 Aug;52(2):248-57 [15282806.001]
  • [Cites] Radiology. 2004 Aug;232(2):585-91 [15205478.001]
  • [Cites] J Magn Reson B. 1994 Oct;105(2):99-112 [7952937.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] Radiology. 1996 Sep;200(3):639-49 [8756909.001]
  • [Cites] J Magn Reson Imaging. 1997 Jan-Feb;7(1):102-10 [9039599.001]
  • [Cites] Nat Med. 1997 Jul;3(7):780-2 [9212107.001]
  • [Cites] Radiology. 1998 Nov;209(2):499-509 [9807580.001]
  • [Cites] Magn Reson Med. 1999 Sep;42(3):467-78 [10467291.001]
  • [Cites] Radiology. 2005 Jan;234(1):79-85 [15618376.001]
  • (PMID = 19004780.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB-00422; United States / NCI NIH HHS / CA / R01 CA120861; United States / NIBIB NIH HHS / EB / R01 EB000422; United States / NINDS NIH HHS / NS / R01 NS-40801; United States / NINDS NIH HHS / NS / R01 NS040801; United States / NCI NIH HHS / CA / R01 CA-120861
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


82. Tang Y, Wang L, Zhang P, Wei H, Gao R, Liu X, Yu Y, Wang L: Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol; 2010 Dec;17(12):1903-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
  • Mucin 1 (MUC1), a tumor-associated antigen, is a transmembrane glycoprotein expressed by normal epithelial cells and overexpressed by carcinomas of epithelial origin.
  • Autoantibodies against MUC1 are often found in circulation, either free or bound to immune complexes, which might contribute to limit tumor outgrowth and dissemination by antibody-dependent cell-mediated cytotoxicity, and were found favorably predictive of survival in early breast cancer patients.
  • The results showed that more patients with benign breast tumors (P = 0.001) and breast cancer patients before primary treatment (P = 0.010) were found to have anti-MUC1 IgG than healthy women; anti-MUC1 IgG before primary treatment was found more than after primary treatment (P = 0.016) in breast cancer patients.
  • Furthermore, we found that circulating anti-MUC1 antibodies may still bind MUC1 shed into blood in stage IV breast cancer, which can support the use of MUC1-target immune therapy strategies.
  • [MeSH-major] Autoantibodies / blood. Breast Neoplasms / diagnosis. Breast Neoplasms / immunology. Mucin-1 / immunology. Recombinant Proteins
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay / methods. Escherichia coli / genetics. Female. Humans. Middle Aged. Sensitivity and Specificity. Tandem Repeat Sequences

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Nov 1;96(9):3147-53 [11049996.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):589-94 [10673204.001]
  • [Cites] Breast Cancer Res Treat. 2001 Sep;69(1):1-11 [11759823.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1217-22 [11953875.001]
  • [Cites] Eur J Cancer. 2002 Jun;38(9):1189-93 [12044504.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):97-100 [12455059.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1130-9 [12966437.001]
  • [Cites] Breast Cancer Res Treat. 2003 Oct;81(3):195-207 [14620915.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1131-5 [15387710.001]
  • [Cites] Urologe A. 1990 Mar;29(2):77-86 [2158684.001]
  • [Cites] Immunol Lett. 1993 Feb;35(2):163-8 [7685318.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2856-60 [7514493.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1325-31 [8869094.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12492-4 [9139698.001]
  • [Cites] Tumour Biol. 1998;19(3):186-95 [9591045.001]
  • [Cites] J Gastroenterol. 1998 Jun;33(3):354-61 [9658314.001]
  • [Cites] Cancer Immunol Immunother. 1998 Jul;46(5):245-52 [9690452.001]
  • [Cites] Am J Surg. 2005 Oct;190(4):570-1 [16164922.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1324-36 [16619287.001]
  • [Cites] BMC Cancer. 2006;6:253 [17064405.001]
  • [Cites] Histol Histopathol. 2007 Aug;22(8):905-22 [17503348.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3060-9 [18483372.001]
  • [Cites] J Thorac Oncol. 2008 Jul;3(7):735-44 [18594319.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1357-63 [18561323.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):574-83 [10653872.001]
  • [Cites] Int J Biol Markers. 2001 Apr-Jun;16(2):112-20 [11471893.001]
  • (PMID = 20876819.001).
  • [ISSN] 1556-679X
  • [Journal-full-title] Clinical and vaccine immunology : CVI
  • [ISO-abbreviation] Clin. Vaccine Immunol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Recombinant Proteins
  • [Other-IDs] NLM/ PMC3008176
  •  go-up   go-down


83. Preda A, Novikov V, Möglich M, Floyd E, Turetschek K, Shames DM, Roberts TP, Corot C, Carter WO, Brasch RC: Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol; 2005 Nov;15(11):2268-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
  • Carboxymethyldextran (CMD)-A2-Gd-DOTA, a slow clearance blood pool contrast agent with a molecular weight of 52.1 kDa, designed to have intravascular residence for more than 1 h, was evaluated for its potential to characterize and differentiate the microvessels of malignant and benign breast tumors.
  • Precontrast single-slice inversion-recovery snapshot FLASH and dynamic contrast-enhanced MRI using an axial T1-weighted three-dimensional spoiled gradient recalled sequence was performed in 30 Sprague-Dawley rats with chemically induced breast tumors.
  • Endothelial transfer coefficient and fractional plasma volume of the breast tumors were estimated from MRI data acquired with CMD-A2-Gd-DOTA enhancement injected at a dose of 0.1 mmol Gd/kg body weight using a two-compartment bidirectional model of the tumor tissue.
  • The correlation between MRI microvessel characteristics and histopathological tumor grade was determined using the Scarff-Bloom-Richardson method.
  • Using CMD-A2-Gd-DOTA, no significant correlations were found between the MR-estimated endothelial transfer coefficient or plasma volumes with histological tumor grade.
  • Analysis of CMD-A2-Gd-DOTA-enhanced MR kinetic data failed to demonstrate feasibility for the differentiation of benign from malignant tumors or for image-based tumor grading.
  • [MeSH-major] Magnetic Resonance Imaging. Mammary Neoplasms, Experimental / blood supply. Mammary Neoplasms, Experimental / pathology. Organometallic Compounds

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 1998;16(4):225-30 [9589031.001]
  • [Cites] Anticancer Res. 1991 Sep-Oct;11(5):1783-92 [1837443.001]
  • [Cites] J Magn Reson Imaging. 1999 Aug;10(2):170-7 [10441021.001]
  • [Cites] Am J Obstet Gynecol. 2000 Oct;183(4):956-63 [11035346.001]
  • [Cites] Sci Am. 1994 Jul;271(1):58-65 [8066425.001]
  • [Cites] J Magn Reson Imaging. 2001 Sep;14(3):237-42 [11536400.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jul-Aug;15(4):621-8 [2061479.001]
  • [Cites] Radiology. 2001 Feb;218(2):562-9 [11161179.001]
  • [Cites] Acta Radiol Suppl. 1997;412:91-9 [9240087.001]
  • [Cites] Invest Radiol. 1994 Jun;29 Suppl 2:S8-11 [7928277.001]
  • [Cites] Radiat Res. 1985 Mar;101(3):460-72 [3983362.001]
  • [Cites] Magn Reson Med. 1990 Oct;16(1):117-31 [2255233.001]
  • [Cites] Magn Reson Med. 1991 Feb;17(2):357-67 [2062210.001]
  • [Cites] Magn Reson Imaging. 1992;10(1):97-108 [1545688.001]
  • [Cites] Radiology. 1996 Mar;198(3):893-8 [8628889.001]
  • [Cites] Magn Reson Med. 1993 May;29(5):616-22 [8505897.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):448-55 [12722742.001]
  • [Cites] Invest Radiol. 1996 May;31(5):288-93 [8724128.001]
  • [Cites] Invest Radiol. 2000 Apr;35(4):213-8 [10764089.001]
  • [Cites] Eur Radiol. 2003 Feb;13(2):354-65 [12599002.001]
  • [Cites] Invest Radiol. 1991 Dec;26(12 ):1035-40 [1722486.001]
  • [Cites] AJR Am J Roentgenol. 1998 Oct;171(4):941-9 [9762973.001]
  • [Cites] Radiology. 1996 Mar;198(3):813-8 [8628876.001]
  • [Cites] J Magn Reson Imaging. 1999 Feb;9(2):177-86 [10077011.001]
  • [Cites] Magn Reson Med. 2001 May;45(5):880-6 [11323815.001]
  • [Cites] Magn Reson Med. 1995 Dec;34(6):845-52 [8598811.001]
  • [Cites] Eur Radiol. 2001;11(7):1276-84 [11471624.001]
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):882-8 [11382948.001]
  • [Cites] Radiology. 1999 Oct;213(1):265-72 [10540670.001]
  • [Cites] Magn Reson Med. 1990 Jan;13(1):77-89 [2319937.001]
  • [Cites] Anticancer Res. 1984 Jan-Apr;4(1-2):5-12 [6712176.001]
  • [Cites] J Magn Reson Imaging. 1999 Jun;9(6):777-85 [10373025.001]
  • [Cites] J Magn Reson Imaging. 1997 Jan-Feb;7(1):82-90 [9039597.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7022-32 [3191477.001]
  • [Cites] Magn Reson Med. 2000 Mar;43(3):403-9 [10725883.001]
  • [Cites] Cancer Metastasis Rev. 1987;6(4):559-93 [3327633.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1299-305 [3040213.001]
  • (PMID = 16012822.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA82923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / carboxymethyl-dextran-A2-gadolinium-DOTA
  •  go-up   go-down


84. John BJ, Griffiths C, Ebbs SR: Pleomorphic adenoma of the breast should be excised with a cuff of normal tissue. Breast J; 2007 Jul-Aug;13(4):418-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma of the breast should be excised with a cuff of normal tissue.
  • Pleomorphic adenoma is a benign tumor found rarely in the breast but commonly in the salivary gland.
  • Unlike the salivary gland variant management guidelines are poorly defined in the breast.
  • We describe the first case of pleomorphic adenoma of the breast that has recurred for the second time following previous surgical excisions, and review the available literature.
  • Clinicians should be aware of the condition, as preoperative diagnosis will facilitate adequate surgery.
  • [MeSH-major] Adenoma, Pleomorphic / surgery. Breast Neoplasms / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Recurrence, Local / surgery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593049.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


85. Eom M, Han A, Yi SY, Shin JJ, Cui Y, Park KH: RHEB expression in fibroadenomas of the breast. Pathol Int; 2008 Apr;58(4):226-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RHEB expression in fibroadenomas of the breast.
  • Although fibroadenoma is one of the most common types of benign breast tumor, genes specific to the tumor have not been identified.
  • RT-PCR for RHEB indicated increased expression of RHEB in fibroadenoma compared to breast cancer.
  • When studied with real-time PCR, the average RHEB/beta-actin ratio in fibroadenoma samples was 1.99, 2.46-fold greater than the average RHEB/beta-actin ratio in breast carcinoma of 0.81 (P < 0.01).
  • Therefore, RHEB could be used cytopathologically to distinguish fibroadenoma from malignant breast carcinomas as a secondary diagnostic tool.
  • [MeSH-major] Breast Neoplasms / genetics. Fibroadenoma / genetics. Gene Expression Regulation, Neoplastic. Monomeric GTP-Binding Proteins / genetics. Neuropeptides / genetics
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Mastectomy. Microdissection. Oligonucleotide Array Sequence Analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18324915.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neuropeptides; 0 / RHEB protein, human; 0 / RNA, Messenger; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  •  go-up   go-down


86. Tse GM, Tan PH, Lui PC, Gilks CB, Poon CS, Ma TK, Law BK, Lam WW: The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol; 2007 Mar;60(3):315-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
  • The evaluation of myoepithelial cells can be helpful, with benign papilloma showing a continuous myoepithelial cell layer, which becomes attenuated or absent in malignant papillary lesions.
  • METHODS: A large series of 100 papillomas (28 papillomas with florid epithelial hyperplasia) and 68 papillary carcinomas (9 invasive, 44 in situ, and 15 ductal carcinomas in situ (DCIS) involving papillomas) of the breast were stained for myoepithelial cells by immunohistochemistry using antibodies to smooth-muscle actin (SMA), p63, CD10 and cytokeratin (CK) 14.
  • CK14 and p63 may be used as an adjunct in assessing difficult papillary lesions of the breast.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. DNA-Binding Proteins / metabolism. Diagnosis, Differential. Female. Humans. Keratin-14 / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Neprilysin / metabolism. Papilloma / metabolism. Papilloma / pathology. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology. Trans-Activators / metabolism. Transcription Factors. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):862-4 [10690183.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Diagn Cytopathol. 2000 Sep;23(3):151-5 [10945900.001]
  • [Cites] Histopathology. 2000 Sep;37(3):232-40 [10971699.001]
  • [Cites] Mod Pathol. 2001 May;14(5):465-71 [11353058.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Histopathology. 2001 Sep;39(3):273-8 [11532038.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):397-405 [11950913.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):101-8 [12109843.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):936-9 [12461063.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):336-40 [12653579.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):20-3 [12704442.001]
  • [Cites] Cancer. 2003 Jun 25;99(3):172-9 [12811858.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):165-71 [14631369.001]
  • [Cites] Histol Histopathol. 2004 Apr;19(2):465-71 [15024707.001]
  • [Cites] Semin Diagn Pathol. 2004 Feb;21(1):32-41 [15074557.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):217-21 [15323138.001]
  • [Cites] Am J Clin Pathol. 2004 Sep;122(3):440-3 [15362376.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1506-12 [15489655.001]
  • [Cites] Clin Immunol Immunopathol. 1975 May;4(1):67-84 [1092499.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):122-33 [7195300.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):451-61 [6351647.001]
  • [Cites] Mod Pathol. 1989 Nov;2(6):569-76 [2479944.001]
  • [Cites] Am J Pathol. 1991 Mar;138(3):751-63 [1705754.001]
  • [Cites] Histopathology. 1991 Jun;18(6):517-22 [1715306.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):315-22 [1384226.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Ann Surg. 1951 Jan;133(1):18-36 [14800254.001]
  • [Cites] Cancer. 1962 May-Jun;15:444-55 [14459407.001]
  • [Cites] Breast J. 2005 Jan-Feb;11(1):2-8 [15647071.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):185-9 [15677540.001]
  • [Cites] Histopathology. 2005 Mar;46(3):320-7 [15720418.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):36-44 [15762278.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):625-32 [15832086.001]
  • [Cites] J Clin Pathol. 2005 Nov;58(11):1185-8 [16254109.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):374-82 [10705818.001]
  • (PMID = 16698948.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Keratin-14; 0 / Neoplasm Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC1860581
  •  go-up   go-down


87. Devi PM, Singh LR, Gatphoh ED: Fibroadenoma with squamous metaplasia. Singapore Med J; 2007 Jul;48(7):682-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroadenoma is the most common benign breast tumour in adolescent and young women.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Fibroadenoma / pathology
  • [MeSH-minor] Adult. Female. Fibrocystic Breast Disease / complications. Fibrocystic Breast Disease / pathology. Humans. Metaplasia / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609833.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


88. Kallel R, Bahri Zouari I, Gouiaa N, Charfi S, Daoud E, Ayadi L, Makni S, Daoud J, Sellami Boudawara T: [Adenoid cystic carcinoma of the breast]. Cancer Radiother; 2009 Jul;13(4):323-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the breast].
  • [Transliterated title] Carcinome adénoïde kystique du sein.
  • Adenoid cystic carcinoma of the breast is a rare neoplasm, accounting for only 0.1% of all malignant breast tumours.
  • The clinical criteria is not specific and the radiographic examination showed a benign-appearing tumour.
  • The preoperative diagnosis is possible with fine-needle aspiration cytology.
  • The diagnosis is made by histological examination, presented a difficult differential diagnosis with cribriform carcinoma; so it is necessary to use histochemical or immunohistochemical techniques.
  • Compared to other locations, adenoid cystic carcinoma of the breast has a favorable prognosis.
  • The aim of our study is to describe the epidemiological, clinicopathological characteristics, the treatment and the prognosis of this rare type of breast tumour.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Adenoid Cystic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Combined Modality Therapy / methods. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464219.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


89. Nguyen QH, Szeto E, Mansberg R, Mansberg V: Paravertebral infection (phlegmon) demonstrated by FDG dual-head coincidence imaging in a patient with multiple malignancies. Clin Nucl Med; 2005 Apr;30(4):241-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 66-year-old woman was referred for a bone scan to assess back pain on a background of breast cancer, melanoma, and rheumatic heart disease.
  • The scan appearance was suspicious for a localized soft tissue neoplasm.
  • Because FDG is not tumor-specific, accumulation in benign lesions may give rise to false-positive results despite a high pretest probability for malignancy.
  • [MeSH-major] Cellulitis / radionuclide imaging. Diagnostic Errors / prevention & control. Fluorodeoxyglucose F18. Lumbar Vertebrae / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Staphylococcal Infections / radionuclide imaging
  • [MeSH-minor] Aged. Back Pain / diagnosis. Back Pain / etiology. Breast Neoplasms / complications. Breast Neoplasms / radionuclide imaging. Diagnosis, Differential. Female. Gamma Cameras. Humans. Melanoma / complications. Melanoma / radionuclide imaging. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764879.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Kooistra B, Wauters C, Strobbe L: Indeterminate breast fine-needle aspiration: repeat aspiration or core needle biopsy? Ann Surg Oncol; 2009 Feb;16(2):281-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indeterminate breast fine-needle aspiration: repeat aspiration or core needle biopsy?
  • Fine-needle aspiration (FNA) of breast lesions provides indeterminate (C1, C3, and C4) diagnoses in a high proportion of cases.
  • The aim of the present study was to retrospectively determine whether repeat FNA or core needle biopsy (CNB) most frequently provides a correct and more conclusive diagnosis.
  • Improvement in preoperative diagnosis by repeat FNA or CNB was defined as C2/B2 in benign lesions, C3/B3 in premalignant lesions, C4/B4 or C5/B5 in malignant lesions where primary FNA was C1, and C5/B5 in malignant lesions where primary FNA was C3 or C4.
  • Among 255 eligible cases, CNB improved the preoperative diagnosis more often than did repeat FNA (78.0% vs. 54.8%, odds ratio = 2.9, P < .001).
  • When corrected for patient age, appearance on mammogram (mass or not), clinical findings (palpable or not), tumor size, and aspiration mode (freehand vs. image guided), this difference slightly increased (odds ratio = 3.0, P = .001).
  • CNB should be performed after an indeterminate FNA of a breast lesion to obtain a reliable and clear preoperative diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Biopsy, Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050965.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Garza-Guajardo R, Mendez-Olvera N, Flores-Gutierrez JP, Hernandez-Martinez S, Candanosa-Mc Cann M, Ancer-Rodriguez J, Barboza-Quintana O: Fine needle aspiration biopsy diagnosis of metastatic neoplasms of the breast. A three-case report. Cytojournal; 2005 Sep 20;2:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy diagnosis of metastatic neoplasms of the breast. A three-case report.
  • Metastases to the breast are unusual lesions that make up approximately 2% of all malignant mammary neoplasms and may mimic both benign and malignant primary neoplasms from a clinical point of view, as well as in imaging studies.
  • Arriving at a correct diagnosis is therefore essential in order to establish appropriate management.
  • We present three cases of metastatic neoplasms diagnosed through fine needle aspiration biopsy and immunocytochemistry.
  • The cytological diagnoses were: medulloblastoma in an 18-year-old woman, melanoma in a 26-year-old man, and an exceptional case of ovarian sarcoma originating from a granulosa cell tumor with metastases to both breasts.
  • A metastatic disease should be considered in the differential diagnosis of a palpable mass in the breast, especially if there is a history of an extramammary malignant neoplasm.
  • Whenever possible the exam of the material obtained should be compared to the previous biopsy, which is usually enough to arrive at a correct diagnosis, thus preventing unnecessary surgical procedures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2001 Aug;439(2):201-5 [11561762.001]
  • [Cites] Acta Cytol. 1996 Nov-Dec;40(6):1293-300 [8960043.001]
  • [Cites] Acta Cytol. 2002 Jan-Feb;46(1):13-8 [11843553.001]
  • [Cites] Acta Cytol. 2002 Mar-Apr;46(2):377-85 [11917589.001]
  • [Cites] Cytopathology. 2003 Aug;14(4):191-4 [12873311.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):854-5 [14624777.001]
  • [Cites] Breast. 2002 Dec;11(6):526-8 [14965721.001]
  • [Cites] J Surg Oncol. 1991 Oct;48(2):112-6 [1921396.001]
  • [Cites] Br J Neurosurg. 1991;5(1):73-5 [2021436.001]
  • [Cites] Am J Clin Pathol. 1989 Jul;92(1):27-35 [2750705.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):291-300 [3473862.001]
  • [Cites] Radiology. 1973 May;107(2):359-62 [4695903.001]
  • [Cites] JAMA. 1971 Oct 4;218(1):97 [5109929.001]
  • [Cites] Diagn Cytopathol. 1994;10(1):33-6 [8005039.001]
  • [Cites] J Am Coll Surg. 1994 Jul;179(1):49-53 [8019724.001]
  • [Cites] Acta Cytol. 1996 Mar-Apr;40(2):384-5 [8629434.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2259-66 [11745279.001]
  • (PMID = 16174298.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1253525
  •  go-up   go-down


92. Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC, Lingle WL: Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res; 2005 May 15;11(10):3722-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer.
  • PURPOSE: We examined the feasibility of using molecular characterization of circulating tumor cells as a method for early detection of breast cancer.
  • RESEARCH DESIGN: Women without a prior history of cancer who had a breast abnormality detected on imaging followed by a breast biopsy were enrolled in this study.
  • Real-time reverse transcription-PCR was used to quantitate the expression levels of the highly breast-specific genes, mammaglobin, gamma-aminobutyric acid type A receptor pi subunit (GABA A(pi)), B305D-C, and B726P in the epithelial cell-enriched samples.
  • From their clinical assessment, 100 patients had benign breast disease, 10 patients had ductal carcinoma in situ, and 44 patients had invasive breast cancer.
  • We constructed a diagnostic test that classified patients with mammaglobin levels of at least 32.2 copies/pg beta-actin (units) in their circulating epithelial cells as positive for invasive breast cancer.
  • A diagnostic test that classified patients as positive for invasive breast cancer when either mammaglobin levels were >46.3 units or B305D-C levels were >11.6 units increased the sensitivity and specificity to 70.5% and 81.0%, respectively.
  • In the latter test, 12 of the 14 node-positive breast cancer patients were correctly identified.
  • CONCLUSIONS: These results suggest that molecular characterization of circulating epithelial cells using mammaglobin and B305D-C offers potential for early detection of invasive breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Gene Expression Profiling. Neoplasm Proteins / biosynthesis. Neoplastic Cells, Circulating. Uteroglobin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Mammaglobin A. Middle Aged. Neoplasm Invasiveness. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7043; author reply 7044 [16203799.001]
  • (PMID = 15897569.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B305D-C protein, human; 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


93. Grabiec M, Nowicki P, Walentowicz M, Greźlikowska U, Mierzwa T, Chmielewska W: [Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients]. Ginekol Pol; 2005 May;76(5):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients].
  • OBJECTIVES: Serum CA-125 is of value in differential diagnosis of benign and malignant adnexal masses, especially in postmenopausal women.
  • In ovarian cancer preoperative CA-125 levels are related to tumor stage, histologic grade, but are not an independent prognostic factor.
  • DESIGN: The aim of our study was to determine CA-125 serum level in women with ovarian tumor treated previously because of breast cancer.
  • All those patients were treated because of breast cancer previously.
  • RESULTS: In 19 women (37,3%) benign ovarian tumors were found, in 4 cases (7,8) - primary ovarian cancer whereas in 28 patients (54,9%) breast cancer metastases were detected.
  • 2. In a group of women with breast cancer and ovarian tumor, metastatic adnexal masses were observed in more than 50% of cases.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / pathology. CA-125 Antigen / blood. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Poland. Preoperative Care / methods. Retrospective Studies. Risk Assessment. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145856.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


94. Lenhard MS, Kahlert S, Himsl I, Ditsch N, Untch M, Bauerfeind I: Phyllodes tumour of the breast: clinical follow-up of 33 cases of this rare disease. Eur J Obstet Gynecol Reprod Biol; 2008 Jun;138(2):217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumour of the breast: clinical follow-up of 33 cases of this rare disease.
  • OBJECTIVE: The "cystosarcoma phyllodes" of the breast is a rare entity which accounts for 0.5% of all breast neoplasms.
  • STUDY DESIGN: The data of 5270 patients with primary breast neoplasms treated in our department between 1984 and 2005 were retrospectively analysed for the histopathologic diagnosis of a cystosarcoma phyllodes.
  • The clinical data was analysed with respect to tumour grading and size, treatment and prognosis.
  • RESULTS: Retrospective analysis of 5270 patients with primary breast neoplasms revealed 33 patients.
  • In the histopathological analysis, tumour grade was classified as benign in 40%, borderline in 27% and malignant in 33% of patients.
  • Breast conserving surgery was conducted in 58% of the patients, mastectomy in 42%.
  • Mean tumour size was 6.9 cm, and no lymph node infiltration was found in the 10 patients who received axillary lymph node dissection.
  • The local recurrence rate was 50% in malignant, 20% in borderline and only 8% in benign tumours.
  • Distant metastases were seen in three patients (9%) with malignant phyllodes tumours.
  • Neither regarding age at primary diagnosis nor in tumour size there was a significant difference between patients with local recurrence or metastatic spread and those without (p=0.284 tumour size; p=0.739 for age; Mann-Whitney U-test).
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868973.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


95. Bisdas S, Baghi M, Huebner F, Mueller C, Knecht R, Vorbuchner M, Ruff J, Gstoettner W, Vogl TJ: In vivo proton MR spectroscopy of primary tumours, nodal and recurrent disease of the extracranial head and neck. Eur Radiol; 2007 Jan;17(1):251-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo proton MR spectroscopy of primary tumours, nodal and recurrent disease of the extracranial head and neck.
  • Benign and malignant neoplasms as well as metastatic lymph nodes of 39 patients were examined using localized single voxel magnetic resonance spectroscopy (MRS) [repetition time (TR) 1500, echo time (TE) 135) at 1.5 T.
  • The Cho/Cr ratios in all malignant neoplasms (mean: 5.2, range: 1.7-17.8) were significantly elevated relative to those in the normal muscle structures (mean: 0.9, range: 0.2-1.4), while those in the benign neoplasms were elevated (mean: 24.4, range: 1.4-59.7) with respect to those in the malignant ones.
  • The average Cho/Cr ratio in the metastatic lymph nodes was significantly higher (mean: 4.8, range: 3.3-5.6) than that for benign lymphoid hyperplasia (mean: 2.2, range: 1.0-3.0).
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Magnetic Resonance Spectroscopy. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jun;86(12):4402-6 [2734292.001]
  • [Cites] Magn Reson Med. 1993 Apr;29(4):436-40 [8385259.001]
  • [Cites] Breast Cancer Res. 2005;7(4):149-52 [15987466.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1696-704 [15569733.001]
  • [Cites] NMR Biomed. 1998 Nov;11(7):360-9 [9859942.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1057-72 [9194433.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1133-8 [10871028.001]
  • [Cites] Radiology. 1997 Sep;204(3):661-6 [9280241.001]
  • [Cites] Eur Radiol. 2005 Apr;15(4):645-52 [15627189.001]
  • [Cites] J Comput Assist Tomogr. 2004 Mar-Apr;28(2):233-46 [15091129.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Mar;25(3):484-90 [15037477.001]
  • [Cites] Am J Med. 1994 Apr;96(4):383-8 [8166160.001]
  • [Cites] NMR Biomed. 1998 Oct;11(6):266-72 [9802468.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):557-65 [15560713.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1381-9 [12873684.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Nov-Dec;21(10):1930-5 [11110549.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Jan;21(1):183-93 [10669248.001]
  • [Cites] Magn Reson Med. 2001 May;45(5):765-9 [11323802.001]
  • [Cites] Invasion Metastasis. 1993;13(2):57-71 [8225853.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3030-4 [15833828.001]
  • (PMID = 16703309.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


96. Min Y, Ren X, Vaught DB, Chen J, Donnelly E, Lynch CC, Lin PC: Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer. Cancer Res; 2010 Apr 1;70(7):2819-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer.
  • Breast to bone metastasis is a common occurrence in the majority of patients with advanced breast cancer.
  • Understanding the underlying mechanisms of how metastatic tumor cells induce bone destruction is critically important.
  • We previously reported that Tie2, a receptor tyrosine kinase, is significantly increased in human breast cancer tissues compared with normal and benign breast tumors and regulates tumor angiogenesis.
  • In this study, we identify a new function of Tie2 in osteoclastogenesis and osteolytic bone invasion of breast cancer.
  • Consistently, neutralization of Tie2 activity in vivo significantly inhibited osteolytic bone invasion and tumor growth in a mammary tumor model, which correlated with a significant reduction of osteoclasts and tumor angiogenesis.
  • These findings identify Tie2 as a therapeutic target for controlling not only tumor angiogenesis but also osteolytic bone metastasis in breast cancer.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol In Vitro. 2001 Aug-Oct;15(4-5):455-61 [11566578.001]
  • [Cites] Ann N Y Acad Sci. 2007 Nov;1117:12-25 [18056034.001]
  • [Cites] Cell. 2004 Jul 23;118(2):149-61 [15260986.001]
  • [Cites] Nature. 1980 Feb 14;283(5748):669-70 [7354855.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):66-80 [1555533.001]
  • [Cites] Osteoporos Int. 1997;7(1):39-43 [9102061.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2072-8 [9329972.001]
  • [Cites] Br J Cancer. 1998;77(1):51-6 [9459145.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8829-34 [9671764.001]
  • [Cites] Stem Cells. 2005;23(1):134-43 [15625130.001]
  • [Cites] Arthritis Rheum. 2005 May;52(5):1585-94 [15880817.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14016-21 [16172397.001]
  • [Cites] Oncogene. 2006 Jul 20;25(31):4257-66 [16518413.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):816-23 [17289872.001]
  • [Cites] Bone. 2007 Apr;40(4):1032-40 [17251073.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2007 Jan;43(1):21-4 [17570030.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 3;362(4):1019-25 [17825261.001]
  • [Cites] Trends Immunol. 2007 Dec;28(12):519-24 [17981504.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • (PMID = 20233869.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108856; United States / NIAMS NIH HHS / AR / R01 AR053718-04; United States / NIAMS NIH HHS / AR / R01 AR053718; United States / NINDS NIH HHS / NS / NS45888; United States / NIAMS NIH HHS / AR / AR053718-04; United States / NCI NIH HHS / CA / R01 CA108856-05; United States / NINDS NIH HHS / NS / R01 NS045888-04; United States / NCI NIH HHS / CA / CA108856-05; United States / NINDS NIH HHS / NS / R01 NS045888; United States / NINDS NIH HHS / NS / NS045888-04; United States / NIAMS NIH HHS / AR / AR053718; United States / NCI NIH HHS / CA / CA108856
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Tek protein, mouse; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, TIE-2
  • [Other-IDs] NLM/ NIHMS174219; NLM/ PMC2848896
  •  go-up   go-down


97. Linda A, Londero V, Mazzarella F, Zuiani C, Bazzocchi M: Rare breast neoplasms: is there any peculiar feature on magnetic resonance mammography? Radiol Med; 2007 Sep;112(6):850-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare breast neoplasms: is there any peculiar feature on magnetic resonance mammography?
  • PURPOSE: The purpose of this study is to describe the semiological features of rare breast neoplasms at magnetic resonance mammography (MRM).
  • MATERIALS AND METHODS: Out of 468 MRMs of patients with a histological diagnosis of breast malignancy, 27 (5.7%) cases of rare breast neoplasms, confirmed by definitive histological analysis on surgical specimens, were selected: four (0.9%) intracystic papillary neoplasms, four (0.9%) intraductal papillary neoplasms, five (1.0%) invasive papillary neoplasms, two (0.4%) medullary carcinomas, seven (1.5%) mucinous carcinomas, three (0.6%) tubular carcinomas, one (0.2%) tubulo-lobular carcinoma and one (0.2%) desmoid tumour.
  • RESULTS: No semiologic features of malignancy or peculiar appearances indicating rare breast neoplasm were identified.
  • On the contrary, MRM appearance was nonspecific and often suggestive of probably benign (Breast Imaging Reporting and Data System-BI-RADS 3) (40%) or benign lesions (BI-RADS 2) (7.5%), or lesions were undetectable at MRM (BI-RADS 1) (7.5%).
  • CONCLUSIONS: Frequently, rare breast neoplasms show low suspicious morphologic and kinetic patterns at MRM, and they are often classified as indeterminate lesions.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Breast / pathology. Contrast Media. Female. Gadolinium DTPA. Humans. Middle Aged. Rare Diseases

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2004 Oct;183(4):1149-57 [15385322.001]
  • [Cites] Semin Roentgenol. 2001 Jul;36(3):226-37 [11475069.001]
  • [Cites] Radiology. 1999 Apr;211(1):101-10 [10189459.001]
  • [Cites] Radiology. 2000 Jul;216(1):248-54 [10887256.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 2000 Aug;60(9):514-9 [11019579.001]
  • [Cites] J Magn Reson Imaging. 1997 May-Jun;7(3):461-4 [9170027.001]
  • [Cites] Pathology. 2002 Aug;34(4):309-14 [12190286.001]
  • [Cites] Eur Radiol. 1997;7(8):1231-4 [9377507.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):1045-53 [16244803.001]
  • [Cites] Radiology. 2002 Sep;224(3):881-8 [12202728.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2487-93 [15330203.001]
  • [Cites] Eur Radiol. 2002 May;12(5):1087-92 [11976850.001]
  • [Cites] AJR Am J Roentgenol. 2005 Aug;185(2):481-7 [16037524.001]
  • [Cites] AJR Am J Roentgenol. 1997 May;168(5):1331-4 [9129437.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1046-52 [16175185.001]
  • [Cites] J Clin Oncol. 2005 Mar 10;23 (8):1678-84 [15755976.001]
  • [Cites] N Engl J Med. 2004 Jul 29;351(5):427-37 [15282350.001]
  • [Cites] Breast Cancer Res Treat. 1997 Aug;45(1):39-46 [9285115.001]
  • [Cites] Eur Radiol. 2005 Sep;15(9):2010-7 [15841382.001]
  • [Cites] Eur Radiol. 2000;10(1):46-58 [10663717.001]
  • [Cites] Br J Radiol. 2000 Aug;73(872):806-18 [11026854.001]
  • [Cites] Clin Radiol. 2000 Dec;55(12):921-8 [11124071.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):115-24 [12585665.001]
  • [Cites] AJR Am J Roentgenol. 2005 Oct;185(4):964-70 [16177416.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1727-41 [15894099.001]
  • [Cites] Radiology. 1999 Dec;213(3):881-8 [10580970.001]
  • [Cites] Eur Radiol. 1996;6(6):929-31 [8972335.001]
  • [Cites] Radiology. 2003 Dec;229(3):893-901 [14593189.001]
  • [Cites] Eur J Surg Oncol. 2001 Dec;27(8):701-6 [11735163.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):832-5 [12766589.001]
  • [Cites] Eur Radiol. 2002 Sep;12(9):2207-10 [12195471.001]
  • [Cites] Radiology. 1999 Aug;212(2):543-9 [10429716.001]
  • [Cites] Radiology. 2001 Jul;220(1):13-30 [11425968.001]
  • [Cites] Clin Imaging. 2005 Nov-Dec;29(6):396-400 [16274892.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1442-8 [10334529.001]
  • [Cites] Eur Radiol. 2002 Sep;12(9):2198-206 [12195470.001]
  • [Cites] AJR Am J Roentgenol. 2003 Dec;181(6):1718-9 [14627606.001]
  • [Cites] Radiol Med. 2002 Oct;104(4):262-72 [12569307.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):179-83 [12076930.001]
  • [Cites] AJR Am J Roentgenol. 1999 Nov;173(5):1323-9 [10541112.001]
  • [Cites] Eur Radiol. 2004 Aug;14(8):1371-9 [14986052.001]
  • [Cites] Br J Radiol. 1997 May;70(833):446-51 [9227224.001]
  • [Cites] AJR Am J Roentgenol. 1995 Feb;164(2):321-6 [7839962.001]
  • [Cites] Radiology. 2000 Dec;217(3):841-8 [11110952.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3 Suppl):89-95 [12585661.001]
  • [Cites] J Comput Assist Tomogr. 1987 Nov-Dec;11(6):1074-6 [3316325.001]
  • (PMID = 17885743.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


98. Huang YL, Lin SH, Chen DR: Computer-Aided Diagnosis Applied to 3-D US of Solid Breast Nodules by Using Principal Component Analysis and Image Retrieval. Conf Proc IEEE Eng Med Biol Soc; 2005;2:1802-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-Aided Diagnosis Applied to 3-D US of Solid Breast Nodules by Using Principal Component Analysis and Image Retrieval.
  • Textural features have been shown to be valuable in tumor diagnosis.
  • This study combines three practical textural features in ultrasound (US) images, i.e. spatial gray-level dependence matrices (SGLDMs), gray-level difference matrix (GLDM) and auto-covariance matrix, to identify breast tumor as benign or malignant.
  • The textural features always perform as a high dimensional vector that is unfavorable to differentiate breast tumors in practice.
  • The principal component analysis (PCA) is used to reduce the dimension of textural feature vector and then the image retrieval technique was utilized to differentiate between benign and malignant tumors.
  • The proposed computer-aided diagnosis (CAD) system differentiates solid breast nodules with a relatively high accuracy in the US imaging and helps inexperienced operators avoid misdiagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17282567.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Chen CJ, Chang RF, Moon WK, Chen DR, Wu HK: 2-D ultrasound strain images for breast cancer diagnosis using nonrigid subregion registration. Ultrasound Med Biol; 2006 Jun;32(6):837-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-D ultrasound strain images for breast cancer diagnosis using nonrigid subregion registration.
  • Tissue elasticity of a lesion is a useful criterion for the diagnosis of breast ultrasound (US).
  • In this study, we evaluate the accuracy of continuous US strain image in the classification of benign from malignant breast tumors.
  • In general, after compression by the US probe, a soft benign tumor will become flatter than a stiffened malignant tumor.
  • We proposed a computer-aided diagnostic (CAD) system by utilizing the nonrigid image registration modality on the analysis of tumor deformation.
  • One-hundred pathology-proven cases, including 60 benign breast tumors and 40 malignant tumors, were used in the experiments to test the classification accuracy of the proposed method.
  • The A(z) value of the support vector machine based on the four characteristic values used for the classification of solid breast tumors was 0.9358.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Diagnosis, Computer-Assisted / methods. Diagnosis, Differential. Elasticity. Female. Humans. Image Processing, Computer-Assisted / methods. Middle Aged. Stress, Mechanical

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785006.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Atalay C, Atalay G, Yilmaz KB, Altinok M: The role of anti-CENP-B and anti-SS-B antibodies in breast cancer. Neoplasma; 2005;52(1):32-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of anti-CENP-B and anti-SS-B antibodies in breast cancer.
  • In this study, anti-SS-B and anti-CENP-B autoantibodies were studied in breast cancer patients and compared to a control group surgically treated due to benign diseases.
  • Fifty-five patients with breast cancer and 25 patients with benign diseases were prospectively included in the study.
  • In the breast cancer group, both anti-CENP-B (33% vs. 8%) and anti-SS-B (44% vs. 24%) autoantibodies had higher positivity compared to the control group, but this difference reached statistical significance only for anti-CENP-B antibodies (p=0.02).
  • Besides, anti-SS-B positivity was detected more frequently in breast cancer patients with axillary involvement (63% vs. 24%) (p=0.006) and increased as the number of involved lymph nodes increased in the axilla (p=0.03).
  • Although the clinical significance of autoantibody detection in cancer patients is still not clear, autoantibodies especially detected in individuals without proven autoimmune diseases needs to be thoroughly evaluated for early diagnosis and treatment of various cancers.
  • [MeSH-major] Antibodies, Antinuclear / immunology. Antibodies, Neoplasm / blood. Autoantigens / immunology. Breast Diseases / immunology. Breast Neoplasms / immunology. Chromosomal Proteins, Non-Histone / immunology. DNA-Binding Proteins / immunology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739023.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Neoplasm; 0 / Autoantigens; 0 / CENPB protein, human; 0 / Centromere Protein B; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SS-B antibodies
  •  go-up   go-down






Advertisement